

CURRICULUM VITAE

Bruce m. Camitta

Professor

Department of Pediatrics

Division of Pediatrics Hematology Oncology Blood and Marrow Transplant

OFFICE ADDRESS:

8701 Watertown Plank Road

Milwaukee, WI 53226

EDUCATION:

1956 - 1959 Far Rockaway High School, New York, NY

1959 - 1961 Wesleyan University, Middletown, CT

1961 - 1963 BS, Johns Hopkins University, Baltimore, MD

1962 - 1966 MD, Johns Hopkins School of Medicine, Baltimore, MD

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

1964 - 1965 NIH post-sophomore research fellow, Johns Hopkins Medical School, MD

1966 - 1968 Intern and Resident, Pediatrics, Children's Hospital of Pittsburgh, Pittsburgh, PA

1968 - 1969 Resident, Pediatrics, Harriet Lane Service, Johns Hopkins Hospital, Baltimore, MD

1971 - 1973 USPHS Research Fellow, Pediatrics, Hematology, Harvard Medical School, MA

MILITARY SERVICE:

1969 - 1971 Captain/Major, United States Air Force

FACULTY APPOINTMENTS:

1973 - 1975 Instructor, Pediatrics, Harvard Medical School, MA

1975 - 1976 Assistant Professor, Pediatrics, Harvard Medical School, MA

1976 - 1977 Assistant Professor, Pediatrics, Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI

1977 - 1982 Associate Professor, Pediatrics, Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI

1982 - Present Professor, Pediatrics, Hematology/Oncology/BMT, Medical College of Wisconsin, Milwaukee, WI

1983 - Present Professor, Medicine, Medical College of Wisconsin, Milwaukee, WI

1985 - Present Tenured Professor, Pediatrics, Medical College of Wisconsin, Milwaukee, WI

ADMINISTRATIVE APPOINTMENTS:

1978 - 2001 Chief, Pediatrics, Hematology/Oncology, Medical College of Wisconsin at Children's Hospital of Wisconsin, Milwaukee, WI

1978 - 2008 Director, Midwest Children's Cancer Center, Milwaukee, WI

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:

1970 - 1971 Chief, Pediatrics, Griffiss Air Force Base Hospital, NY

1973 - 1974 Assistant in Medicine, Hematology, Children's Hospital Boston, Boston, MA

1974 - 1976 Associate in Medicine, Children's Hospital Boston, Boston, MA

1974 - 1976 Associate in Hematology/Oncology, Children's Hospital Boston, Boston, MA

1974 - 1976 Assistant Director, Clinical Hematology/Oncology, Children's Hospital and the Sidney Farber Cancer Institute, Boston, MA

1975 - 1976 Senior Clinical Associate, Sidney Farber Cancer Institute, Boston, MA
 1975 - 1976 Assistant in Medicine, Peter Bent Brigham Hospital, Boston, MA
 1997 - Present Rebecca Jean Slye Professor of Pediatric Oncology, Children's Hospital of Wisconsin, Milwaukee, WI

HOSPITAL STAFF PRIVILEGES:

1976 - 1998 Medical Staff, Pediatrics, Milwaukee County Hospital, Milwaukee, WI
 1976 - Present Medical Staff, Hematology/Oncology/BMT, Children's Hospital of Wisconsin, Milwaukee, WI

SPECIALTY BOARDS AND CERTIFICATION:

<u>Board Certified</u>	<u>Issue Date</u>	<u>Expiration</u>
National Board of Medical Examiners	1967	None
American Board of Pediatrics	1971	None
Pediatric Hematology/Oncology	1976	None

<u>Licensure</u>	<u>Number</u>	<u>Issue Date</u>	<u>Expiration</u>
New York		1969	1973
Massachusetts		1971	1976
Wisconsin	19850-20	1976	10/31/2017

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

1975 - Present American Society of Hematology (ASH) (Member)
 1975 - Present American Society of Clinical Oncology (ASCO) (Member)
 1975 - Present American Association for Cancer Research (AACR) (Member)
 1976 - 1996 Milwaukee Pediatric Society (Member)
 1982 - 1999 Pediatric Oncology Group (POG) (Member)
 1989 - Present American Pediatric Society (Member)
 1994 - Present American Society for Blood and Marrow Transplantation (ASBMT) (Member)
 1999 - Present Children's Oncology Group (COG) (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Editorial Board
 1987 - 1989 Journal of Clinical Oncology
 1994 - 2004 International Journal of Pediatric Hematology Oncology
 1995 - 1997 Journal of Clinical Oncology
 2003 - Present Journal of Pediatric Hematology- Oncology
 Journal Review
 Pediatrics
 Cancer
 International Journal of Pediatric Hematology Oncology
 Journal of Clinical Oncology
 Journal of Pediatric Hematology-Oncology
 Journal of Pediatrics
 Leukemia
 Medical and Pediatric Oncology
 New England Journal of Medicine
 Blood
 Archives Internal Medicine
 Annals of Internal Medicine
 American Journal of Medicine
 Bone Marrow Transplantation

NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

1983 - 1999 Member, New ALL Core Committee, Pediatric Oncology Group
1983 Member, Internal Site Visit Committee, Pediatric Oncology Group
1984 - 1993 Member, AML Core Committee, Pediatric Oncology Group
1987 - 1988 Chairperson, Biologic Response Modifiers Subcommittee, Pediatric Oncology Group
1988 - 1993 Chairperson, New Agents/Pharmacology Committee, Pediatric Oncology Group
1989 - 1999 Auditor, Pediatric Oncology Group
1993 - 2009 Member, Medical Advisory Board, Aplastic Anemia Foundation of America
1993 - 1999 Chairperson, New ALL Committee, Pediatric Oncology Group
1994 - 1999 Member, PI Core Committee, Pediatric Oncology Group
1995 - 2008 Chairperson, Pediatric Cancer Committee, International Bone Marrow Transplant Registry (IBMTR)
1995 - Present Member, Pediatric Cancer Committee, International Bone Marrow Transplant Registry (IBMTR)
1995 - 2003 Member, Aplastic Anemia Subcommittee, International Bone Marrow Transplant Registry (IBMTR)
1996 - 2003 Chairperson, Medical Board, Aplastic Anemia Foundation of America
1997 - 2003 Member, Executive Committee, Autologous Blood and Marrow Transplant Registry
1999 - 2006 Auditor, Children's Oncology Group
1999 - 2000 Co-Chair, ALL Committee, Children's Oncology Group
1999 - 2012 Member, ALL Core Committee, Children's Oncology Group
2000 - 2002 Chairperson, ALL Committee, Children's Oncology Group
2002 - 2004 Member, Medical Advisory Board, National Childhood Cancer Foundation (NCCF)/Cure Search
2003 - Present Member, Non-malignant Disorders Subcommittee, International Bone Marrow Transplant Registry (IBMTR)
2003 Member, Medical Advisory Board, Gilda's Club
2003 - 2004 Member, Administration Review Task Force, Children's Oncology Group
2007 - 2012 Chairperson, Switch Study DSMB, National Heart Lung Blood Institute (NHLBI)
2010 - 2016 Chairperson, Twitch Study DSMB, National Heart Lung Blood Institute (NHLBI)

INTERNATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:

2014 - Present Director of Hematology-Oncology Development program, Angkor Hospital for Children, Siem Reap, Cambodia

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

International

1976 Kyoto, Japan
1978 Ulm, Germany
1984 Tokyo, Japan
1990 Paris, France
2004 Tokyo, Japan
1997 Moscow, Russia
1998 Rejkavik, Iceland
1998 Buenos Aires, Argentina
1997 Sao Paulo, Brazil
1995 Paris, France

National

1983 NIH Conference on Aplastic Anemia - Airlie, Virginia

PEER REVIEWED WORKSHOPS/PRESENTATIONS:

National

Chen I, Harvey R, Mullighan CG, Loh ML, Devidas M, Borowitz MJ, Tasian SK, Payne-turner D, Wharton W, Pullen J, Carroll AJ, Carroll WL, Camitta BM, Hunger S, Winick NJ, Willman CL, Relationship of CRLF2 expression and outcome in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): a report from the Children's Oncology Group, American Society of Clinical Oncology - Oral Presentation, Chicago, IL, 2011

COMMITTEE SERVICE:**Medical College of Wisconsin**

1982 Member, Radiation Therapy Search Committee, Medical College of Wisconsin
1982 - 1986 Member, Institutional Research Committee, Medical College of Wisconsin
1984 - 2015 Member, Housestaff Recruitment Committee, Pediatrics, Medical College of Wisconsin
1984 - 1985 Member, Executive Committee, Cancer Center, Medical College of Wisconsin
1984 - 1985 Member, Surgery Five Year Review Committee, Medical College of Wisconsin
1984 - 1993 Executive Committee, Dept of Pediatrics, Medical College of Wisconsin
1984 - 1993 Member, Promotions Committee, Pediatrics, Medical College of Wisconsin
1986 - 1987 Vice President, Faculty Assembly, Medical College of Wisconsin
1987 Member, Ad hoc Committee on Ethics in Research, Medical College of Wisconsin
1987 - 1988 President, Faculty Assembly, Medical College of Wisconsin
1989 - 1993 Member, Governance Committee, Medical College of Wisconsin
1990 - 2004 Member, Housestaff Evaluation Committee, Pediatrics, Medical College of Wisconsin
1992 - 1998 Chairperson, Cancer Center Research Review Committee, Medical College of Wisconsin
1993 - 2008 Member, Section Head Committee, Medical College of Wisconsin
1995 - 1996 Member, Ad Hoc Committee on Promotion Policies, Medical College of Wisconsin
1996 Chairperson, Vice-Chair for Research Search Committee, Pediatrics, Medical College of Wisconsin
1996 Member, Surgery Search Committee, Medical College of Wisconsin
1999 - 2000 Member, Medicine Internal Review Committee, Medical College of Wisconsin
2001 - Present Member, Pediatric Data Safety Monitoring Board, Medical College of Wisconsin
2004 - 2005 Member, Ad hoc Committee on Ethics in Research, Medical College of Wisconsin
2005 Member, Ad hoc Committee on Institutional Review Boards, Medical College of Wisconsin
2015 - Present Chairperson, Data Safety Monitoring Board, Cancer Center of the Medical College

Hospital

1977 - Present Chairperson, Tumor Board, Children's Hospital of Wisconsin
1978 - 2015 Vice-Chairperson, Human Rights Review Committee, Children's Hospital of Wisconsin
1978 Member, Site Selection Committee, Children's Hospital of Wisconsin
1978 - 1988 Member, Medical Records Committee, Children's Hospital of Wisconsin
1985 - 1988 Member, REAL Task Force Committee, Children's Hospital of Wisconsin
1987 - 1993 Medical Director, Hospice Program, Children's Hospital of Wisconsin
1988 - 1993 Member, Quality Assurance Committee, Children's Hospital of Wisconsin
1989 - 1995 Member, Clinical Pastoral Education Advisory Committee, Children's Hospital of Wisconsin
1990 Member, Psychiatry Search Committee, Children's Hospital of Wisconsin
1994 - 2008 Member, HOT Unit Redesign Committee, Children's Hospital of Wisconsin
1996 - 2003 Member, Medical Records Committee, Children's Hospital of Wisconsin
1998 - 2003 Member, Advanced Practice Nursing Committee, Children's Hospital of Wisconsin
1999 - 2006 Member, Standards of Care Committee, Children's Specialty Group
2004 - 2008 Member, Pathology Search Committee, Children's Hospital of Wisconsin
2015 - Present Interim chairman IRB2, Peds Hem/Onc, Children's Hospital of Wisconsin

MCW TEACHING ACTIVITIES:**Medical Student Education**

1982 - 2001 MS3 Anemia Lecture
1995 - Present MS1 Biochemistry Problem-Based Learning

Resident and Fellow Education

1976 - 2012 Ward Attending General Pediatrics
1976 - Present Ward Attending Oncology
1977 - 2006 PL3 Intake Rounds
1989 - Present PL-1 Journal Club
1991 - 1996 Grand Rounds Case of the Week

Continuing Medical Education

- Grand Rounds Presentation - The Spleen
- Grand Rounds Presentation - The ESR
- Grand Rounds Presentation - Treatment of Childhood ALL
- Grand Rounds Presentation - Bone Pain in Leukemia
- Grand Rounds Presentation - Aplastic Anemia
- Grand Rounds Presentation - Acute Lymphocytic Leukemia
- Grand Rounds Presentation - Superior Vena Cava Syndrome
- Grand Rounds Presentation - Anemia of Prematurity
- Grand Rounds Presentation - Autoimmune Hemolytic Anemia
- Grand Rounds Presentation - G-6-PD Deficiency

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. Medearis DN Jr, **Camitta BM**, Heath EC. Cell wall composition and virulence in Escherichia coli. *J Exp Med.* 1968 Sep 01;128(3):399-414. PMID: PMC2138529
2. **Camitta BM**, Nathan DG, Forman EN, Parkman R, Rapoport JM, Orellana TD. Posthepatic severe aplastic anemia--an indication for early bone marrow transplantation. *Blood.* 1974 Apr;43(4):473-83.
3. Levine MD, **Camitta BM**, Nathan D, Curran WJ. The medical ethics of bone marrow transplantation in childhood. *J Pediatr.* 1975 Jan;86(1):145-50.
4. **Camitta BM**, Nathan DG. Anemia in adolescence. 1. Disturbances of iron balance. *Postgrad Med.* 1975 Feb;57(2):143-6.
5. **Camitta BM**, Nathan DG. Anemia in adolescence. 2. Hemoglobinopathies and other causes. *Postgrad Med.* 1975 Feb;57(2):151-5.
6. **Camitta BM**, Rapoport JM, Parkman R, Nathan DG. Selection of patients for bone marrow transplantation in severe aplastic anemia. *Blood.* 1975 Mar;45(3):355-63.
7. Boxer LA, **Camitta BM**, Berenberg W, Fanning JP. Myelofibrosis-myeloid metaplasia in childhood. *Pediatrics.* 1975 Jun;55(6):861-5.
8. Cassady JR, Order S, **Camitta B**, Marck A. Modification of gastrointestinal symptoms following irradiation by low dose rate technique. *Int J Radiat Oncol Biol Phys.* 1975;1(1-2):15-20.
9. Furman L, **Camitta BM**, Jaffe N, Sallan SE, Cassady JR, Traggis D, Leavitt P, Nathan DG, Frei E 3rd. Development of an effective treatment program for childhood acute lymphocytic leukemia: a preliminary report. *Med Pediatr Oncol.* 1976;2(2):157-66.
10. Parkman R, Rosen FS, Rapoport J, **Camitta B**, Levey RL, Nathan DG. Detection of genetically determined histocompatibility antigen differences between HL-A identical and MLC nonreactive siblings. *Transplantation.* 1976 Feb;21(2):110-6.
11. Dritschilo A, Cassady JR, **Camitta B**, Jaffe N, Furman L, Traggis D. The role of irradiation in central nervous system treatment and prophylaxis for acute lymphoblastic leukemia. *Cancer.* 1976 Jun;37(6):2729-35.
12. **Camitta BM**, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP, Rapoport JM, Storb R. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. *Blood.* 1976 Jul;48(1):63-70.
13. Albert E, Thomas ED, Nisperos B, Storb R, **Camitta BM**, Parkman R. Hla antigens and haplotypes in 200 patients with aplastic anemia. *Transplantation.* 1976 Nov;22(5):528-31.
14. Sallan SE, **Camitta BM**, Chan DM, Traggis D, Jaffe N. Chemotherapy with cyclophosphamide, vincristine, cytosine arabinoside, and prednisone (COAP) in childhood acute lymphoblastic leukemia (ALL). *Med Pediatr Oncol.* 1977;3(4):359-64.
15. Sallan SE, **Camitta BM**, Frei E 3rd, Furman L, Leavitt P, Bishop Y, Jaffe N. Clinical and cytokinetic aspects of remission induction of childhood acute lymphoblastic leukemia (ALL): addition of an anthracycline to vincristine and prednisone. *Med Pediatr Oncol.* 1977;3(3):281-7.
16. Lasser SD, **Camitta BM**, Needleman HL. Dental management of patients undergoing bone marrow transplantation for aplastic anemia. *Oral Surg Oral Med Oral Pathol.* 1977 Feb;43(2):181-9.
17. **Camitta BM**, Quesenberry PJ, Parkman R, Boxer LA, Stossel TP, Cassady JR, Rapoport JM, Nathan DG. Bone marrow transplantation for an infant with neutrophil dysfunction. *Exp Hematol.* 1977

- Mar;5(2):109-16.
18. Ausman LM, Gallina DL, **Camitta BM**, Flath LC, Hegsted DM. Acute erythroid hypoplasia in malnourished infant squirrel monkeys fed isolated soy protein. *Am J Clin Nutr.* 1977 Oct;30(10):1713-20.
 19. Chambers CH, **Camitta BM**, Garg U, Tang TT, McCreadie SR. Nephroblastoma (Wilms tumor): tubule density and prognosis. *Med Pediatr Oncol.* 1978;5(1):127-35.
 20. **Camitta BM**, Holcenberg JS. Safety of delayed leucovorin "rescue" following high-dose methotrexate in children. *Med Pediatr Oncol.* 1978;5(1):55-9.
 21. Parkman R, Rapoport J, **Camitta B**, Levey R, Rosen FS. Prognostic value of antibody-dependent assays for presensitization in bone marrow transplant recipients. *Transplant Proc.* 1978 Mar;10(1):71-3.
 22. **Camitta BM**. A.L.G. in aplastic anaemia. *Lancet.* 1978 Mar 04;1(8062):504.
 23. Kun LE, **Camitta BM**. Hepatopathy following irradiation and adriamycin. *Cancer.* 1978 Jul;42(1):81-4.
 24. **Camitta BM**, Thomas ED. Severe aplastic anaemia: a prospective study of the effect of androgens or transplantation on haematological recovery and survival. *Clin Haematol.* 1978 Oct;7(3):587-95.
 25. Parkman R, Rapoport J, **Camitta B**, Levey RH, Nathan DG. Successful use of multiagent immunosuppression in the bone marrow transplantation of sensitized patients. *Blood.* 1978 Dec;52(6):1163-9.
 26. **Camitta BM**. Pathogenesis of severe aplastic anemia: inferences from therapeutic trials. *Haematol Blood Transfus.* 1979;24:161-5.
 27. **Camitta BM**. The role of viral infections in aplastic anemia. *Haematol Blood Transfus.* 1979;24:39-46.
 28. **Camitta BM**, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rapoport JM, Santos G, Gordon-Smith EC, Storb R. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. *Blood.* 1979 Mar;53(3):504-14.
 29. Holcenberg JS, **Camitta BM**, Borella LD, Ring BJ. Phase I study of succinylated acinetobacter L-glutaminase-L-asparaginase. *Cancer Treat Rep.* 1979 Jun;63(6):1025-30.
 30. Jumean HG, **Camitta B**, Holcenberg J, Hodach A. Desacetyl vinblastine amide sulfate induced ineffective erythropoiesis. *Cancer.* 1979 Jul;44(1):64-8.
 31. Holcenberg JS, Borella LD, **Camitta BM**, Ring BJ. Human pharmacology and toxicology of succinylated Acinetobacter glutaminase-asparaginase. *Cancer Res.* 1979 Aug;39(8):3145-51.
 32. **Camitta BM**, Pinkel D, Thatcher LG, Casper J, Kun LE, Lauer S. Failure of early intensive chemotherapy to improve prognosis in childhood acute lymphocytic leukemia. *Med Pediatr Oncol.* 1980;8(4):383-9.
 33. Jacobs PA, **Camitta BM**, Sullivan DM. Current therapy of childhood osteosarcoma and Ewing's sarcoma. *Wis Med J.* 1980 Apr;79(4):22-4.
 34. Chusid MJ, Pisciotta AV, Duquesnoy RJ, **Camitta BM**, Tomasulo PA. Congenital neutropenia: studies of pathogenesis. *Am J Hematol.* 1980;8(3):315-24.
 35. Weinstein HJ, Mayer RJ, Rosenthal DS, **Camitta BM**, Coral FS, Nathan DG, Frei E 3rd. Treatment of acute myelogenous leukemia in children and adults. *N Engl J Med.* 1980 Aug 28;303(9):473-8.
 36. Rapoport JM, Parkman R, Newburger P, **Camitta BM**, Chusid MJ. Correction of infantile agranulocytosis (Kostmann's syndrome) by allogeneic bone marrow transplantation. *Am J Med.* 1980 Apr;68(4):605-9.
 37. Tang TT, Holcenberg JS, Duck SC, Hodach AE, Oechler HW, **Camitta BM**. Thyroid carcinoma following treatment for acute lymphoblastic leukemia. *Cancer.* 1980 Oct 01;46(7):1572-6.
 38. Lauer ME, **Camitta BM**. Home care for dying children: a nursing model. *J Pediatr.* 1980 Dec;97(6):1032-5.
 39. Holcenberg JS, **Camitta BM**. Recent approaches to the treatment of acute lymphocytic leukemia in childhood. *Annu Rev Pharmacol Toxicol.* 1981;21:231-49.
 40. Chusid MJ, Casper JT, Adair SE, **Camitta BM**. Neutropenia in dysgammaglobulinemia I: remission with immunoglobulin therapy. *Wis Med J.* 1981 Mar;80(3):32-3.
 41. Kun LE, Tang TT, Sty JR, **Camitta BM**. Primary cerebral germinoma and ventriculoperitoneal shunt metastasis. *Cancer.* 1981 Jul 01;48(1):213-6.
 42. Mulhern RK, Crisco JJ, **Camitta BM**. Patterns of communication among pediatric patients with leukemia, parents, and physicians: prognostic disagreements and misunderstandings. *J Pediatr.* 1981 Sep;99(3):480-3.
 43. Kamen BA, Nylen PA, **Camitta BM**, Bertino JR. Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. *Br J Haematol.* 1981 Nov;49(3):355-60.
 44. Kien CL, **Camitta BM**. Protein-energy nutritional status of pediatric cancer patients. *Am J Clin Nutr.* 1981 Nov;34(11):2486-92.
 45. Pinkel D, **Camitta B**, Kun L, Howarth C, Tang T. Doxorubicin cardiomyopathy in children with left-sided

- Wilms tumor. *Med Pediatr Oncol*. 1982;10(5):483-8.
46. Lauer S, Piaskowski V, **Camitta B**, Casper J. Bone marrow and extramedullary variations of cell membrane antigen expression in childhood lymphoid neoplasias at relapse. *Leuk Res*. 1982;6(6):769-74.
 47. **Camitta BM**, Storb R, Thomas ED. Aplastic anemia (first of two parts): pathogenesis, diagnosis, treatment, and prognosis. *N Engl J Med*. 1982 Mar 18;306(11):645-52.
 48. **Camitta BM**, Storb R, Thomas ED. Aplastic anemia (second of two parts): pathogenesis, diagnosis, treatment, and prognosis. *N Engl J Med*. 1982 Mar 25;306(12):712-8.
 49. Kelly KJ, Chusid MJ, **Camitta BM**. Splenic torsion in an infant associated with secondary disseminated *Hemophilus influenzae* infection. *Clin Pediatr (Phila)*. 1982 Jun;21(6):365-6.
 50. **Camitta B**, Kun L, Glicklich M, Oechler H, Adair S, Pinkel D. Doxorubicin-vincristine therapy for Wilms' tumor: a pilot study. *Cancer Treat Rep*. 1982 Oct;66(10):1791-4.
 51. Lauer ME, Mulhern RK, Wallskog JM, **Camitta BM**. A comparison study of parental adaptation following a child's death at home or in the hospital. *Pediatrics*. 1983 Jan;71(1):107-12.
 52. Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, **Camitta BM**, Gelber RD, Nathan DG, Frei E 3rd. The treatment of acute myelogenous leukemia in children and adults: VAPA update. *Haematol Blood Transfus*. 1983;28:41-5.
 53. Harb JM, Werlin SL, **Camitta BM**, Oechler H, Kamin BA, Blank EL. Hepatic ultrastructure in leukemic children treated with methotrexate and 6-mercaptopurine. *Am J Pediatr Hematol Oncol*. 1983;5(4):323-31.
 54. Duquesnoy RJ, Zeevi A, Marrari M, Hackbarth S, **Camitta B**. Bone marrow transplantation for severe aplastic anemia using a phenotypically HLA-identical, SB-compatible unrelated donor. *Transplantation*. 1983 Jun;35(6):566-71.
 55. Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, **Camitta BM**, Gelber RD. Chemotherapy for acute myelogenous leukemia in children and adults: VAPA update. *Blood*. 1983 Aug;62(2):315-9.
 56. **Camitta B**, O'Reilly RJ, Sensenbrenner L, Rapoport J, Champlin R, Doney K, August C, Hoffmann RG, Kirkpatrick D, Stuart R, Santos G, Parkman R, Gale RP, Storb R, Nathan D. Antithoracic duct lymphocyte globulin therapy of severe aplastic anemia. *Blood*. 1983 Oct;62(4):883-8.
 57. Kien CL, **Camitta BM**. Increased whole-body protein turnover in sick children with newly diagnosed leukemia or lymphoma. *Cancer Res*. 1983 Nov;43(11):5586-92.
 58. Casper JT, Lauer SJ, Kirchner PA, Gottschall JL, **Camitta BM**. Evaluation of cerebrospinal fluid mononuclear cells obtained from children with acute lymphocytic leukemia: advantages of combining cytomorphology and terminal deoxynucleotidyl transferase. *Am J Clin Pathol*. 1983 Nov;80(5):666-70.
 59. O'Reilly RJ, **Camitta B**, Nathan DG. Antithoracic duct lymphocyte globulin. *Blood*. 1983 Dec;62(6):1304.
 60. **Camitta BM**. A controlled prospective trial of antithoracic duct lymphocyte globulin (ATDLG) for treatment of severe aplastic anemia. *Prog Clin Biol Res*. 1984;148:239-47.
 61. **Camitta BM**. Pathogenesis and treatment of aplastic anemia. *Rinsho Ketsueki*. 1984 Apr;25(4):459-69.
 62. Tang TT, Harb JM, Oechler HW, **Camitta BM**. Multilocular renal cyst: electron microscopic evidence of pathogenesis. *Am J Pediatr Hematol Oncol*. 1984;6(1):27-32.
 63. Kelly KJ, Neu J, **Camitta BM**, Honig GR. Methemoglobinemia in an infant treated with the folk remedy glycerited asafoetida. *Pediatrics*. 1984 May;73(5):717-9.
 64. Kun LE, **Camitta BM**, Mulhern RK, Lauer SJ, Kline RW, Casper JT, Kamen BA, Kaplan BM, Barber SW. Treatment of meningeal relapse in childhood acute lymphoblastic leukemia. I. Results of craniospinal irradiation. *J Clin Oncol*. 1984 May;2(5):359-64.
 65. Chusid MJ, Casper JT, **Camitta BM**. Editors have ethical responsibilities, too. *N Engl J Med*. 1984 Oct 11;311(15):990-1.
 66. Lauer SJ, Lyman S, Kirchner PA, Gottschall JL, **Camitta BM**, Casper JT. Terminal transferase surveillance of remission bone marrows in childhood acute lymphoblastic leukemia: improved sensitivity with countercurrent centrifugal elutriation. *J Clin Lab Immunol*. 1985 Jan;16(1):17-22.
 67. Lauer ME, Mulhern RK, Bohne JB, **Camitta BM**. Children's perceptions of their sibling's death at home or hospital: the precursors of differential adjustment. *Cancer Nurs*. 1985 Feb;8(1):21-7.
 68. **Camitta BM**, Lauer SJ, Casper JT, Kirchner PA, Kun LE, Oechler HW, Adair SE. Effectiveness of a six-drug regimen (APO) without local irradiation for treatment of mediastinal lymphoblastic lymphoma in children. *Cancer*. 1985 Aug 15;56(4):738-41.
 69. Tang TT, Harb JM, Dunne WM Jr, Wells RG, Meyer GA, Chusid MJ, Casper JT, **Camitta BM**. Cerebral toxoplasmosis in an immunocompromised host. A precise and rapid diagnosis by electron microscopy.

- Am J Clin Pathol. 1986 Jan;85(1):104-10.
70. **Camitta BM**, Casper JT, Kun LE, Lauer SJ, Starshak RJ, Oechler HW. Isolated bilateral T-cell renal lymphoblastic lymphoma. *Am J Pediatr Hematol Oncol.* 1986;8(1):8-12.
 71. Chusid MJ, Casper JT, **Camitta BM**, McCreadie SR. Cyclic neutropenia in identical twins. *Am J Med.* 1986 May;80(5):994-6.
 72. Lauer ME, Mulhern RK, Hoffmann RG, **Camitta BM**. Utilization of hospice/home care in pediatric oncology. A national survey. *Cancer Nurs.* 1986 Jun;9(3):102-7.
 73. Tang TT, Lauer SJ, Harb JM, Kirchner PA, Adair SE, **Camitta BM**. Childhood primary cutaneous non-T/non-B lymphoma followed by acute T-cell leukemia. *Cancer.* 1986 Jun 15;57(12):2368-74.
 74. Kamen BA, Casper J, Lauer S, **Camitta BM**, Holcenberg JS. Treatment of refractory acute lymphoblastic leukemia with teniposide and cytarabine. *Cancer Treat Rep.* 1986 Jul;70(7):935-6.
 75. Rivera GK, Buchanan G, Boyett JM, **Camitta B**, Ochs J, Kalwinsky D, Amylon M, Vietti TJ, Crist WM. Intensive retreatment of childhood acute lymphoblastic leukemia in first bone marrow relapse. A Pediatric Oncology Group Study. *N Engl J Med.* 1986 Jul 31;315(5):273-8.
 76. Weinstein H, Grier H, Gelber R, **Camitta B**, Link M, Delorey M, Price K. Postremission induction intensive sequential chemotherapy for children with AML--treatment results and prognostic factors. *Haematol Blood Transfus.* 1987;30:88-92.
 77. Kien CL, **Camitta BM**. Close association of accelerated rates of whole body protein turnover (synthesis and breakdown) and energy expenditure in children with newly diagnosed acute lymphocytic leukemia. *JPEN J Parenter Enteral Nutr.* 1987;11(2):129-34.
 78. Grier HE, Gelber RD, **Camitta BM**, Delorey MJ, Link MP, Price KN, Leavitt PR, Weinstein HJ. Prognostic factors in childhood acute myelogenous leukemia. *J Clin Oncol.* 1987 Jul;5(7):1026-32.
 79. Lauer SJ, **Camitta BM**. Management of children with cancer. *Wis Med J.* 1987 Sep;86(9):31-2.
 80. **Camitta BM**. Criteria for severe aplastic anaemia. *Lancet.* 1988 Feb 06;1(8580):303-4.
 81. Graham-Pole J, **Camitta B**, Casper J, Elfenbein G, Gross S, Herzig R, Koch P, Mahoney D, Marcus R, Munoz L. Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study. *Bone Marrow Transplant.* 1988 Nov;3(6):559-66.
 82. Bunin NJ, Casper JT, Chitambar C, Hunter J, Truitt R, Menitove J, **Camitta BM**, Ash R. Partially matched bone marrow transplantation in patients with myelodysplastic syndromes. *J Clin Oncol.* 1988 Dec;6(12):1851-5.
 83. Bunin N, **Camitta B**. Oral fluconazole for treatment of disseminated fungal infection. *Pediatr Infect Dis J.* 1989 Jan;8(1):62.
 84. Champlin RE, Horowitz MM, van Bekkum DW, **Camitta BM**, Elfenbein GE, Gale RP, Gluckman E, Good RA, Rimm AA, Rozman C. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. *Blood.* 1989 Feb;73(2):606-13.
 85. Lauer ME, Mulhern RK, Schell MJ, **Camitta BM**. Long-term follow-up of parental adjustment following a child's death at home or hospital. *Cancer.* 1989 Mar 01;63(5):988-94.
 86. Lauer SJ, Kirchner PA, **Camitta BM**. Identification of leukemic cells in the cerebrospinal fluid from children with acute lymphoblastic leukemia: advances and dilemmas. *Am J Pediatr Hematol Oncol.* 1989;11(1):64-73.
 87. Barrett AJ, Horowitz MM, Gale RP, Biggs JC, **Camitta BM**, Dicke KA, Gluckman E, Good RA, Herzig RH, Lee MB. Marrow transplantation for acute lymphoblastic leukemia: factors affecting relapse and survival. *Blood.* 1989 Aug 01;74(2):862-71.
 88. **Camitta B**, Leventhal B, Lauer S, Shuster JJ, Adair S, Casper J, Civin C, Graham M, Mahoney D, Munoz L. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study. *J Clin Oncol.* 1989 Oct;7(10):1539-44.
 89. **Camitta B**, Ash R, Menitove J, Murray K, Lawton C, Hunter J, Casper J. Bone marrow transplantation for children with severe aplastic anemia: use of donors other than HLA-identical siblings. *Blood.* 1989 Oct;74(5):1852-7.
 90. Grier HE, Gelber RD, Clavell LA, **Camitta BM**, Link MP, Garcea MJ, Weinstein HJ. Intensive sequential chemotherapy for children with acute myelogenous leukemia. *Haematol Blood Transfus.* 1990;33:193-7.
 91. **Camitta BM**, Doney K. Immunosuppressive therapy for aplastic anemia: indications, agents, mechanisms, and results. *Am J Pediatr Hematol Oncol.* 1990;12(4):411-24.

92. Tang TT, Segura AD, Oechler HW, Harb JM, Adair SE, Gregg DC, **Camitta BM**, Franciosi RA. Inflammatory myofibrohistiocytic proliferation simulating sarcoma in children. *Cancer*. 1990 Apr 01;65(7):1626-34.
93. Longeway K, Mulhern R, Crisco J, Kun L, Lauer S, Casper J, **Camitta B**, Hoffman RG. Treatment of meningeal relapse in childhood acute lymphoblastic leukemia: II. A prospective study of intellectual loss specific to CNS relapse and therapy. *Am J Pediatr Hematol Oncol*. 1990;12(1):45-50.
94. Wyatt DT, Lum LG, Casper J, Hunter J, **Camitta B**. Autoimmune thyroiditis after bone marrow transplantation. *Bone Marrow Transplant*. 1990 May;5(5):357-61.
95. Tebbi CK, Krischer J, Fernbach DJ, Mahoney DH, Alvarado C, **Camitta B**. Toxicity of high-dose cytosine arabinoside in the treatment of advanced childhood tumors resistant to conventional therapy. A Pediatric Oncology Group study. *Cancer*. 1990 Nov 15;66(10):2064-7.
96. Steuber CP, Holbrook T, **Camitta B**, Land VJ, Sexauer C, Krischer J. Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study. *Invest New Drugs*. 1991 May;9(2):181-4.
97. Krischer JP, Ragab AH, Kun L, Kim TH, Laurent JP, Boyett JM, Cornell CJ, Link M, Luthy AR, **Camitta B**. Nitrogen mustard, vincristine, procarbazine, and prednisone as adjuvant chemotherapy in the treatment of medulloblastoma. A Pediatric Oncology Group study. *J Neurosurg*. 1991 Jun;74(6):905-9.
98. **Camitta B**, Wells R, Segura A, Unni KK, Murray K, Dunn D. Osteoblastoma response to chemotherapy. *Cancer*. 1991 Sep 01;68(5):999-1003.
99. Tang TT, Whelan HT, Meyer GA, Strother DR, Blank EL, **Camitta BM**, Franciosi RA. Optic chiasm glioma associated with inappropriate secretion of antidiuretic hormone, cerebral ischemia, nonobstructive hydrocephalus and chronic ascites following ventriculoperitoneal shunting. *Childs Nerv Syst*. 1991 Dec;7(8):458-61.
100. Grier HE, Gelber RD, Link MP, **Camitta BP**, Clavell LA, Weinstein HJ. Intensive sequential chemotherapy for children with acute myelogenous leukemia: VAPA, 80-035, and HI-C-Daze. *Leukemia*. 1992;6 Suppl 2:48-51.
101. Hows J, Szydlo R, Anasetti C, **Camitta B**, Gajewski J, Gluckman E. Unrelated donor marrow transplants for severe acquired aplastic anemia. *Bone Marrow Transplant*. 1992;10 Suppl 1:102-6.
102. Gluckman E, Auerbach A, Ash RC, Biggs JC, Bortin MM, **Camitta BM**, Champlin RE, Friedrich W, Gale RP, Good RA. Allogeneic bone marrow transplants for Fanconi anemia. A preliminary report from the International Bone Marrow Transplant Registry. *Bone Marrow Transplant*. 1992;10 Suppl 1:53-7.
103. Gluckman E, Horowitz MM, Champlin RE, Hows JM, Bacigalupo A, Biggs JC, **Camitta BM**, Gale RP, Gordon-Smith EC, Marmont AM. Bone marrow transplantation for severe aplastic anemia: influence of conditioning and graft-versus-host disease prophylaxis regimens on outcome. *Blood*. 1992 Jan 01;79(1):269-75.
104. Bunin NJ, Casper JT, Lawton C, Murray K, **Camitta BM**, Greenwood M, Geil J, Ash RC. Allogeneic marrow transplantation using T cell depletion for patients with juvenile chronic myelogenous leukemia without HLA-identical siblings. *Bone Marrow Transplant*. 1992 Feb;9(2):119-22.
105. Truitt RL, Piaskowski V, Kirchner P, McOlash L, **Camitta BM**, Casper JT. Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial. *J Immunother (1991)*. 1992 May;11(4):274-85.
106. Lauer SJ, **Camitta BM**, Leventhal BG, Mahoney DH Jr, Shuster JJ, Adair S, Casper JT, Civin CI, Graham M, Kiefer G. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. *Cancer*. 1993 May 01;71(9):2854-61.
107. **Camitta BM**, Rock A. Acute lymphoid leukemia in a patient with thrombocytopenia/absent radii (Tar) syndrome. *Am J Pediatr Hematol Oncol*. 1993 Aug;15(3):335-7.
108. Werlin SL, Wyatt D, **Camitta B**. Effect of abrupt discontinuation of high glucose infusion rates during parenteral nutrition. *J Pediatr*. 1994 Mar;124(3):441-4.
109. **Camitta B**, Chusid MJ, Starshak RJ, Gottschall JL. Use of irradiated lymphocytes from immune donors for treatment of disseminated varicella. *J Pediatr*. 1994 Apr;124(4):593-6.
110. Flomenberg P, Babbitt J, Drobyski WR, Ash RC, Carrigan DR, Sedmak GV, McAuliffe T, **Camitta B**, Horowitz MM, Bunin N. Increasing incidence of adenovirus disease in bone marrow transplant recipients. *J Infect Dis*. 1994 Apr;169(4):775-81.
111. Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, **Camitta B**, Garbrecht F. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic

- myelogenous leukemia. *Blood*. 1994 Apr 01;83(7):1980-7.
112. **Camitta B**, Mahoney D, Leventhal B, Lauer SJ, Shuster JJ, Adair S, Civin C, Munoz L, Steuber P, Strother D. Intensive intravenous methotrexate and mercaptopurine treatment of higher-risk non-T, non-B acute lymphocytic leukemia: A Pediatric Oncology Group study. *J Clin Oncol*. 1994 Jul;12(7):1383-9.
 113. Barrett AJ, Horowitz MM, Pollock BH, Zhang MJ, Bortin MM, Buchanan GR, **Camitta BM**, Ochs J, Graham-Pole J, Rowlings PA. Bone marrow transplants from HLA-identical siblings as compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission. *N Engl J Med*. 1994 Nov 10;331(19):1253-8.
 114. Baxter-Lowe LA, Keever C, Dinauer D, Daniels T, Johnson K, **Camitta B**, Drobyski W, Garbrecht F, Horowitz M, Pietryga D. Use of solid phase automated sequencing to define HLA disparity between bone marrow donors and recipients. *Transplant Proc*. 1995 Feb;27(1):1377-8.
 115. Djordjevic S, Roberts DL, Wang M, Shea T, Camitta MG, Masters BS, Kim JJ. Crystallization and preliminary x-ray studies of NADPH-cytochrome P450 reductase. *Proc Natl Acad Sci U S A*. 1995 Apr 11;92(8):3214-8. PMID: PMC42136
 116. Casper J, **Camitta B**, Truitt R, Baxter-Lowe LA, Bunin N, Lawton C, Murray K, Hunter J, Pietryga D, Garbrecht F. Unrelated bone marrow donor transplants for children with leukemia or myelodysplasia. *Blood*. 1995 May 01;85(9):2354-63.
 117. Mahoney DH Jr, **Camitta BM**, Leventhal BG, Shuster JJ, Civin CJ, Ganick DJ, Lauer SJ, Steuber CP, Kamen BA. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. *Cancer*. 1995 May 15;75(10):2623-31.
 118. Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen EP, Drobyski WR, Ash RC, Horowitz MM, **Camitta B**, Lawton C. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. *Bone Marrow Transplant*. 1995 Aug;16(2):271-5.
 119. Gluckman E, Auerbach AD, Horowitz MM, Sobocinski KA, Ash RC, Bortin MM, Butturini A, **Camitta BM**, Champlin RE, Friedrich W, Good RA, Gordon-Smith EC, Harris RE, Klein JP, Ortega JJ, Pasquini R, Ramsay NK, Speck B, Vowels MR, Zhang MJ, Gale RP. Bone marrow transplantation for Fanconi anemia. *Blood*. 1995 Oct 01;86(7):2856-62.
 120. Smith M, Arthur D, **Camitta B**, Carroll AJ, Crist W, Gaynon P, Gelber R, Heerema N, Korn EL, Link M, Murphy S, Pui CH, Pullen J, Reamon G, Sallan SE, Sather H, Shuster J, Simon R, Trigg M, Tubergen D, Uckun F, Ungerleider R. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. *J Clin Oncol*. 1996 Jan;14(1):18-24.
 121. **Camitta BM**. Treatment of rhabdomyosarcoma. *J Clin Oncol*. 1996 Jan;14(1):323.
 122. Mahoney DH Jr, Strother D, **Camitta B**, Bowen T, Ghim T, Pick T, Wall D, Yu L, Shuster JJ, Friedman H. High-dose melphalan and cyclophosphamide with autologous bone marrow rescue for recurrent/progressive malignant brain tumors in children: a pilot pediatric oncology group study. *J Clin Oncol*. 1996 Feb;14(2):382-8.
 123. Graham ML, Shuster JJ, Kamen BA, Land VJ, Borowitz MJ, **Camitta B**, Cheo DL, Harrison MP, Leventhal BG, Pinkel DP, Pullen DJ, Steuber P, Whitehead VM. Changes in red blood cell methotrexate pharmacology and their impact on outcome when cytarabine is infused with methotrexate in the treatment of acute lymphocytic leukemia in children: a pediatric oncology group study. *Clin Cancer Res*. 1996 Feb;2(2):331-7.
 124. Steuber CP, Krischer J, Holbrook T, **Camitta B**, Land V, Sexauer C, Mahoney D, Weinstein H. Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study. *J Clin Oncol*. 1996 May;14(5):1521-5.
 125. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J, Carroll A, Inoue S, **Camitta B**, Weinstein HJ. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. Pediatric Oncology Group. *N Engl J Med*. 1996 May 30;334(22):1428-34.
 126. Margolis D, **Camitta B**, Pietryga D, Keever-Taylor C, Baxter-Lowe LA, Pierce K, Kupst MJ, French J 3rd, Truitt R, Lawton C, Murray K, Garbrecht F, Flomenberg N, Casper J. Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults. *Br J Haematol*. 1996 Jul;94(1):65-72.
 127. **Camitta BM**, Pullen J, Murphy S. Biology and treatment of acute lymphocytic leukemia in children. *Semin Oncol*. 1997 Feb;24(1):83-91.

128. Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, **Camitta BM**, Pui CH, Downing JR, Behm FG. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. *Blood*. 1997 Feb 15;89(4):1143-6.
129. Kawanishi Y, Passweg J, Drobyski WR, Rowlings P, Cook-Craig A, Casper J, Pietryga D, Garbrecht F, **Camitta B**, Horowitz M, Juckett M, Margolis D, Flomenberg N, Keever-Taylor CA. Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation. *Bone Marrow Transplant*. 1997 Jun;19(11):1069-77.
130. Borowitz MJ, Shuster J, Carroll AJ, Nash M, Look AT, **Camitta B**, Mahoney D, Lauer SJ, Pullen DJ. Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study. *Blood*. 1997 Jun 01;89(11):3960-6.
131. Matherly LH, Taub JW, Wong SC, Simpson PM, Ekizian R, Buck S, Williamson M, Amylon M, Pullen J, **Camitta B**, Ravindranath Y. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. *Blood*. 1997 Jul 15;90(2):578-89.
132. Passweg JR, Socié G, Hinterberger W, Bacigalupo A, Biggs JC, **Camitta BM**, Champlin RE, Gale RP, Gluckman E, Gordon-Smith EC, Hows JM, Klein JP, Nugent ML, Pasquini R, Rowlings PA, Speck B, Tichelli A, Zhang MJ, Horowitz MM, Bortin MM. Bone marrow transplantation for severe aplastic anemia: has outcome improved? *Blood*. 1997 Jul 15;90(2):858-64.
133. Mahoney DH Jr, Shuster J, Nitschke R, Lauer SJ, Winick N, Steuber CP, **Camitta B**. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. *J Clin Oncol*. 1998 Jan;16(1):246-54.
134. Link CJ Jr, Burt RK, Traynor AE, Drobyski WR, Seregina T, Levy JP, Gordon L, Rosen ST, Burns WH, **Camitta B**, Casper J, Horowitz M, Juckett M, Lawton C, Margolis D, Pietryga D, Rowlings P, Taylor C, Furtado M, Stefka J, Gupta-Burt S, Kaiser H, Vesole DH. Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. *HGTRI 0103. Hum Gene Ther*. 1998 Jan 01;9(1):115-34.
135. Whitehead VM, Vuchich MJ, Cooley L, Lauer SJ, Mahoney DH, Shuster JJ, Payment C, Bernstein ML, Akabutu JJ, Bowen T, Kamen BA, Watson MS, Look AT, Pullen DJ, **Camitta B**. Translocations involving chromosome 12p11-13, methotrexate metabolism, and outcome in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. *Clin Cancer Res*. 1998 Jan;4(1):183-8.
136. Passweg JR, Tiberghien P, Cahn JY, Vowels MR, **Camitta BM**, Gale RP, Herzig RH, Hoelzer D, Horowitz MM, Ifrah N, Klein JP, Marks DI, Ramsay NK, Rowlings PA, Weisdorf DJ, Zhang MJ, Barrett AJ. Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. *Bone Marrow Transplant*. 1998 Jan;21(2):153-8.
137. Hunger SP, Fall MZ, **Camitta BM**, Carroll AJ, Link MP, Lauer SJ, Mahoney DH, Pullen DJ, Shuster JJ, Steuber CP, Cleary ML. E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study. *Blood*. 1998 Feb 01;91(3):1021-8.
138. Lauer SJ, **Camitta BM**, Leventhal BG, Mahoney D Jr, Shuster JJ, Kiefer G, Pullen J, Steuber CP, Carroll AJ, Kamen B. Intensive alternating drug pairs after remission induction for treatment of infants with acute lymphoblastic leukemia: A Pediatric Oncology Group Pilot Study. *J Pediatr Hematol Oncol*. 1998;20(3):229-33.
139. Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, **Camitta B**. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study. *J Clin Oncol*. 1998 May;16(5):1712-22.
140. Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, **Camitta B**, Casper J, Drobyski WR, Hanson G, Horowitz M, Lawton C, Margolis J, Peitryga D, Vesole D. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up. *Bone Marrow Transplant*. 1998 May;21(9):893-9.
141. Shuster JJ, Wacker P, Pullen J, Humbert J, Land VJ, Mahoney DH Jr, Lauer S, Look AT, Borowitz MJ, Carroll AJ, **Camitta B**. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. *J Clin Oncol*. 1998 Aug;16(8):2854-63.

142. Borowitz MJ, Rubnitz J, Nash M, Pullen DJ, **Camitta B**. Surface antigen phenotype can predict TEL-AML1 rearrangement in childhood B-precursor ALL: a Pediatric Oncology Group study. *Leukemia*. 1998 Nov;12(11):1764-70.
143. Whitehead VM, Vuchich MJ, Cooley LD, Lauer SJ, Mahoney DH, Shuster JJ, Payment C, Koch PA, Akabutu JJ, Bowen T, Kamen BA, Ravindranath Y, Emami A, Look AT, Beardsley GP, Pullen DJ, **Camitta B**. Accumulation of methotrexate polyglutamates, ploidy and trisomies of both chromosomes 4 and 10 in lymphoblasts from children with B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group Study. *Leuk Lymphoma*. 1998 Nov;31(5-6):507-19.
144. Rubnitz JE, **Camitta BM**, Mahmoud H, Raimondi SC, Carroll AJ, Borowitz MJ, Shuster JJ, Link MP, Pullen DJ, Downing JR, Behm FG, Pui CH. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3) translocation. *J Clin Oncol*. 1999 Jan;17(1):191-6.
145. Amylon MD, Shuster J, Pullen J, Berard C, Link MP, Wharam M, Katz J, Yu A, Laver J, Ravindranath Y, Kurtzberg J, Desai S, **Camitta B**, Murphy SB. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. *Leukemia*. 1999 Mar;13(3):335-42.
146. Pullen J, Shuster JJ, Link M, Borowitz M, Amylon M, Carroll AJ, Land V, Look AT, McIntyre B, **Camitta B**. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (POG) study. *Leukemia*. 1999 Nov;13(11):1696-707.
147. Davies SM, Ramsay NK, Klein JP, Weisdorf DJ, Bolwell B, Cahn JY, **Camitta BM**, Gale RP, Giralt S, Heilmann C, Henslee-Downey PJ, Herzig RH, Hutchinson R, Keating A, Lazarus HM, Milone GA, Neudorf S, Perez WS, Powles RL, Prentice HG, Schiller G, Socié G, Vowels M, Wiley J, Yeager A, Horowitz MM. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia. *J Clin Oncol*. 2000 Jan;18(2):340-7.
148. **Camitta BM**. What is the definition of cure for aplastic anemia? *Acta Haematol*. 2000;103(1):16-8.
149. Woo MH, Shuster JJ, Chen C, Bash RO, Behm FG, **Camitta B**, Felix CA, Kamen BA, Pui CH, Raimondi SC, Winick NJ, Amylon MD, Relling MV. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. *Leukemia*. 2000 Feb;14(2):232-7.
150. Kaleem Z, Shuster JJ, Carroll AJ, Borowitz MJ, Pullen DJ, **Camitta BM**, Zutter MM, Watson MS. Acute lymphoblastic leukemia with an unusual t(8;14)(q11.2;q32): a Pediatric Oncology Group Study. *Leukemia*. 2000 Feb;14(2):238-40.
151. Pollock BH, DeBaun MR, **Camitta BM**, Shuster JJ, Ravindranath Y, Pullen DJ, Land VJ, Mahoney DH Jr, Lauer SJ, Murphy SB. Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study. *J Clin Oncol*. 2000 Feb;18(4):813-23.
152. Laver JH, Barredo JC, Amylon M, Schwenn M, Kurtzberg J, **Camitta BM**, Pullen J, Link MP, Borowitz M, Ravindranath Y, Murphy SB, Shuster J. Effects of cranial radiation in children with high risk T cell acute lymphoblastic leukemia: a Pediatric Oncology Group report. *Leukemia*. 2000 Mar;14(3):369-73.
153. Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer S, Steuber CP, **Camitta B**. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: A Pediatric Oncology Group study. *J Clin Oncol*. 2000 Mar;18(6):1285-94.
154. Aricò M, Valsecchi MG, **Camitta B**, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui CH, Masera G. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. *N Engl J Med*. 2000 Apr 06;342(14):998-1006.
155. Griffin TC, Shuster JJ, Buchanan GR, Murphy SB, **Camitta BM**, Amylon MD. Slow disappearance of peripheral blood blasts is an adverse prognostic factor in childhood T cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. *Leukemia*. 2000 May;14(5):792-5.
156. Chang M, Raimondi SC, Ravindranath Y, Carroll AJ, **Camitta B**, Gresik MV, Steuber CP, Weinstein H. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome and acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) Study 8821. *Leukemia*. 2000 Jul;14(7):1201-7.
157. **Camitta BM**. *Childhood Leukemias* by C-H Pui, MD (ed); Cambridge University Press, 1999, 567 pages. *Leukemia*. 2000 Jul;14(7):1332.
158. Harris MB, Shuster JJ, Pullen J, Borowitz MJ, Carroll AJ, Behm FG, **Camitta B**, Land VJ. Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group Study. *Leukemia*. 2000 Sep;14(9):1570-6.
159. Schneider NR, Carroll AJ, Shuster JJ, Pullen DJ, Link MP, Borowitz MJ, **Camitta BM**, Katz JA, Amylon MD. New recurring cytogenetic abnormalities and association of blast cell karyotypes with prognosis

- in childhood T-cell acute lymphoblastic leukemia: a pediatric oncology group report of 343 cases. *Blood*. 2000 Oct 01;96(7):2543-9.
160. Schrappe M, **Camitta B**, Pui CH, Eden T, Gaynon P, Gustafsson G, Janka-Schaub GE, Kamps W, Masera G, Sallan S, Tsuchida M, Vilmer E. Long-term results of large prospective trials in childhood acute lymphoblastic leukemia. *Leukemia*. 2000 Dec;14(12):2193-4.
161. Maloney KW, Shuster JJ, Murphy S, Pullen J, **Camitta BA**. Long-term results of treatment studies for childhood acute lymphoblastic leukemia: Pediatric Oncology Group studies from 1986-1994. *Leukemia*. 2000 Dec;14(12):2276-85.
162. Pui CH, Mahmoud HH, Wiley JM, Woods GM, Leverger G, **Camitta B**, Hastings C, Blaney SM, Relling MV, Reaman GH. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma. *J Clin Oncol*. 2001 Feb 01;19(3):697-704.
163. Nijhawan A, Baselga E, Gonzalez-Ensenat MA, Vicente A, Southern JF, **Camitta BM**, Esterly NB, Drolet BA. Vesiculopustular eruptions in Down syndrome neonates with myeloproliferative disorders. *Arch Dermatol*. 2001 Jun;137(6):760-3.
164. Lauer SJ, Shuster JJ, Mahoney DH Jr, Winick N, Toledano S, Munoz L, Kiefer G, Pullen JD, Steuber CP, **Camitta BM**. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial. *Leukemia*. 2001 Jul;15(7):1038-45.
165. Whitehead VM, Payment C, Cooley L, Lauer SJ, Mahoney DH, Shuster JJ, Vuchich MJ, Bernstein ML, Look AT, Pullen DJ, **Camitta B**. The association of the TEL-AML1 chromosomal translocation with the accumulation of methotrexate polyglutamates in lymphoblasts and with ploidy in childhood B-progenitor cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. *Leukemia*. 2001 Jul;15(7):1081-8.
166. Pui CH, Jeha S, Irwin D, **Camitta B**. Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial. *Leukemia*. 2001 Oct;15(10):1505-9.
167. Shao L, Diccianni MB, Tanaka T, Gribo R, Yu AL, Pullen JD, **Camitta BM**, Yu J. Thioredoxin expression in primary T-cell acute lymphoblastic leukemia and its therapeutic implication. *Cancer Res*. 2001 Oct 01;61(19):7333-8.
168. Camitta MG, Gabel SA, Chulada P, Bradbury JA, Langenbach R, Zeldin DC, Murphy E. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. *Circulation*. 2001 Nov 13;104(20):2453-8.
169. Broome HE, Yu AL, Diccianni M, **Camitta BM**, Monia BP, Dean NM. Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs. *Leuk Res*. 2002 Mar;26(3):311-6.
170. Ogden AK, Pollock BH, Bernstein ML, **Camitta B**, Buchanan GR. Intermediate-dose methotrexate and intravenous 6-mercaptopurine chemotherapy for children with acute lymphoblastic leukemia who did not respond to initial induction therapy. *J Pediatr Hematol Oncol*. 2002;24(3):182-7.
171. Ramakers-van Woerden NL, Pieters R, Rots MG, van Zantwijk CH, Noordhuis P, Beverloo HB, Peters GJ, van Wering ER, **Camitta BM**, Pui CH, Relling MV, Evans WE, Veerman AJ. Infants with acute lymphoblastic leukemia: no evidence for high methotrexate resistance. *Leukemia*. 2002 May;16(5):949-51.
172. Winter SS, Sweatman J, Shuster JJ, Link MP, Amylon MD, Pullen J, **Camitta BM**, Larson RS. Bone marrow stroma-supported culture of T-lineage acute lymphoblastic leukemic cells predicts treatment outcome in children: a Pediatric Oncology Group study. *Leukemia*. 2002 Jun;16(6):1121-6.
173. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W, Silverman LB, Biondi A, Harms DO, Vilmer E, Schrappe M, **Camitta B**. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. *Lancet*. 2002 Jun 01;359(9321):1909-15.
174. Shuster J, Link M, **Camitta B**, Pullen J, Behm F. Minimax two-stage-designs with applications to tissue banking case-control studies. *Stat Med*. 2002 Sep 15;21(17):2479-93.
175. Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, Bash RO, Behm FG, **Camitta BM**, Pui CH, Raimondi SC, Relling MV. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. *Pharmacogenetics*. 2002 Nov;12(8):605-11.
176. Kupst MJ, Penati B, Debban B, **Camitta B**, Pietryga D, Margolis D, Murray K, Casper J. Cognitive and psychosocial functioning of pediatric hematopoietic stem cell transplant patients: a prospective

- longitudinal study. *Bone Marrow Transplant*. 2002 Nov;30(9):609-17.
177. Litzow MR, Pérez WS, Klein JP, Bolwell BJ, **Camitta B**, Copelan EA, Gale RP, Giralt SA, Keating A, Lazarus HM, Marks DI, McCarthy PL, Miller CB, Milone G, Prentice HG, Russell JA, Schultz KR, Trigg ME, Weisdorf DJ, Horowitz MM. Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission. *Br J Haematol*. 2002 Dec;119(4):1115-24.
178. Milazzo AS, Golioto A, Camitta MG, O'Laughlin MP. An infant with subvalvar and valvar aortic stenosis, subvalvar and valvar pulmonary stenosis, severe biventricular hypertrophy and pulmonary hemorrhage. *Pediatr Cardiol*. 2003;24(2):169-71.
179. Pui CH, Chessells JM, **Camitta B**, Baruchel A, Biondi A, Boyett JM, Carroll A, Eden OB, Evans WE, Gardner H, Harbott J, Harms DO, Harrison CJ, Harrison PL, Heerema N, Janka-Schaub G, Kamps W, Masera G, Pullen J, Raimondi SC, Richards S, Riehm H, Sallan S, Sather H, Shuster J, Silverman LB, Valsecchi MG, Vilmer E, Zhou Y, Gaynon PS, Schrappe M. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. *Leukemia*. 2003 Apr;17(4):700-6.
180. Borowitz MJ, Pullen DJ, Shuster JJ, Viswanatha D, Montgomery K, Willman CL, **Camitta B**, Children's Oncology Group study. Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children's Oncology Group study. *Leukemia*. 2003 Aug;17(8):1566-72.
181. Browning MB, **Camitta BM**. The surgeon's role in pediatric orbital malignancies: an oncologist's perspective. *Ophthalmic Plast Reconstr Surg*. 2003 Sep;19(5):340-4.
182. Abed N, Casper JT, **Camitta BM**, Margolis D, Trost B, Orentas R, Chang CC. Evaluation of histogenesis of B-lymphocytes in pediatric EBV-related post-transplant lymphoproliferative disorders. *Bone Marrow Transplant*. 2004 Feb;33(3):321-7.
183. Ramakers-van Woerden NL, Beverloo HB, Veerman AJ, **Camitta BM**, Loonen AH, van Wering ER, Slater RM, Harbott J, den Boer ML, Ludwig WD, Haas OA, Janka-Schaub GE, Pieters R. In vitro drug-resistance profile in infant acute lymphoblastic leukemia in relation to age, MLL rearrangements and immunophenotype. *Leukemia*. 2004 Mar;18(3):521-9.
184. Heerema NA, Harbott J, Galimberti S, **Camitta BM**, Gaynon PS, Janka-Schaub G, Kamps W, Basso G, Pui CH, Schrappe M, Auclerc MF, Carroll AJ, Conter V, Harrison CJ, Pullen J, Raimondi SC, Richards S, Riehm H, Sather HN, Shuster JJ, Silverman LB, Valsecchi MG, Aricò M, Acute Lymphoblastic Leukemia Study Groups, ALL-BFM, CoALL, AIEOP, DCLSG, FRALLE, CCG, DFCl, POG, St Jude, UKALL. Secondary cytogenetic aberrations in childhood Philadelphia chromosome positive acute lymphoblastic leukemia are nonrandom and may be associated with outcome. *Leukemia*. 2004 Apr;18(4):693-702.
185. Schuetz EG, Relling MV, Kishi S, Yang W, Das S, Chen P, Cook EH, Rosner GL, Pui CH, Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, Bash RO, Behm FG, **Camitta BM**, Raimondi SC, Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J, Lim R, Lim HL, Ong AB, Lee HS, Kuehl P, Zhang J, Lin Y, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS. PharmGKB update: II. CYP3A5, cytochrome P450, family 3, subfamily A, polypeptide 5. *Pharmacol Rev*. 2004 Jun;56(2):159.
186. Bell BA, Brockway GN, Shuster JJ, Erdmann G, Sterikoff S, Bostrom B, **Camitta BM**, Pediatric Oncology Group study (now The Children's Oncology Group). A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group). *Pediatr Blood Cancer*. 2004 Aug;43(2):105-9.
187. Godder K, Eapen M, Laver JH, Zhang MJ, **Camitta BM**, Wayne AS, Gale RP, Doyle JJ, Yu LC, Chen AR, Garvin JH Jr, Sandler ES, Yeager AM, Edwards JR, Horowitz MM. Autologous hematopoietic stem-cell transplantation for children with acute myeloid leukemia in first or second complete remission: a prognostic factor analysis. *J Clin Oncol*. 2004 Sep 15;22(18):3798-804.
188. Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, **Camitta BM**, Champlin RE, Ringdén O, Bredeson CN, Martino R, Gale RP, Cairo MS, Litzow MR, deLima M. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. *Bone Marrow Transplant*. 2004 Oct;34(8):721-7.
189. Jeha S, Kantarjian H, Irwin D, Shen V, Shenoy S, Blaney S, **Camitta B**, Pui CH. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated

- hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial. *Leukemia*. 2005 Jan;19(1):34-8.
190. **Camitta BM**. Pyrite or true gold? Case 1. *J Pediatr Hematol Oncol*. 2005 Feb;27(2):61.
191. Whitehead VM, Shuster JJ, Vuchich MJ, Mahoney DH Jr, Lauer SJ, Payment C, Koch PA, Cooley LD, Look AT, Pullen DJ, **Camitta B**. Accumulation of methotrexate and methotrexate polyglutamates in lymphoblasts and treatment outcome in children with B-progenitor-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. *Leukemia*. 2005 Apr;19(4):533-6.
192. Sutcliffe MJ, Shuster JJ, Sather HN, **Camitta BM**, Pullen J, Schultz KR, Borowitz MJ, Gaynon PS, Carroll AJ, Heerema NA. High concordance from independent studies by the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) associating favorable prognosis with combined trisomies 4, 10, and 17 in children with NCI Standard-Risk B-precursor Acute Lymphoblastic Leukemia: a Children's Oncology Group (COG) initiative. *Leukemia*. 2005 May;19(5):734-40.
193. Burns K, **Camitta B**. Pyrite or true gold? *J Pediatr Hematol Oncol*. 2005 May;27(5):244-5.
194. Baker KS, Loberiza FR Jr, Yu H, Cairo MS, Bolwell BJ, Bujan-Boza WA, **Camitta BM**, Garcia JJ, Ho WG, Liesveld JL, Maharaj D, Marks DI, Schultz KR, Wiernik P, Zander AR, Horowitz MM, Keating A, Weisdorf DJ. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. *J Clin Oncol*. 2005 Oct 01;23(28):7032-42.
195. Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, **Camitta B**. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group. *Cytometry B Clin Cytom*. 2005 Nov;68(1):18-24.
196. Hahn T, Wall D, **Camitta B**, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL Jr. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review. *Biol Blood Marrow Transplant*. 2005 Nov;11(11):823-61.
197. Ravindranath Y, Chang M, Steuber CP, Becton D, Dahl G, Civin C, **Camitta B**, Carroll A, Raimondi SC, Weinstein HJ, Pediatric Oncology Group. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. *Leukemia*. 2005 Dec;19(12):2101-16.
198. Burns K, **Camitta B**. Pyrite or true gold? *J Pediatr Hematol Oncol*. 2005 Dec;27(12):696-8.
199. Eapen M, Rubinstein P, Zhang MJ, **Camitta BM**, Stevens C, Cairo MS, Davies SM, Doyle JJ, Kurtzberg J, Pulsipher MA, Ortega JJ, Scaradavou A, Horowitz MM, Wagner JE. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months. *J Clin Oncol*. 2006 Jan 01;24(1):145-51.
200. Talano JM, Casper JT, **Camitta BM**, Keever-Taylor CA, Murray KJ, Eapen M, Pierce KL, Margolis DA. Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL. *Bone Marrow Transplant*. 2006 Jan;37(2):135-41.
201. Hahn T, Wall D, **Camitta B**, Davies S, Dillon H, Gaynon P, Larson RA, Parsons S, Seidenfeld J, Weisdorf D, McCarthy PL Jr. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. *Biol Blood Marrow Transplant*. 2006 Jan;12(1):1-30.
202. Passweg JR, Pérez WS, Eapen M, **Camitta BM**, Gluckman E, Hinterberger W, Hows JM, Marsh JC, Pasquini R, Schrezenmeier H, Socié G, Zhang MJ, Bredeson C. Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. *Bone Marrow Transplant*. 2006 Apr;37(7):641-9.
203. Mahoney DH Jr, **Camitta BM**, Devidas M. Does intravenous 6-mercaptopurine decrease salvage after relapse in childhood acute lymphoblastic leukemia? *Pediatr Blood Cancer*. 2006 May 01;46(5):660-1.
204. Eapen M, Raetz E, Zhang MJ, Muehlenbein C, Devidas M, Abshire T, Billett A, Homans A, **Camitta B**, Carroll WL, Davies SM, Children's Oncology Group, Center for International Blood and Marrow Transplant Research. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. *Blood*. 2006 Jun 15;107(12):4961-7. PMID: PMC1895819
205. Barredo JC, Devidas M, Lauer SJ, Billett A, Marymont M, Pullen J, **Camitta B**, Winick N, Carroll W, Ritchey AK. Isolated CNS relapse of acute lymphoblastic leukemia treated with intensive systemic chemotherapy and delayed CNS radiation: a pediatric oncology group study. *J Clin Oncol*. 2006 Jul

- 01;24(19):3142-9.
206. Schultz KR, Pullen DJ, Sather HN, Shuster JJ, Devidas M, Borowitz MJ, Carroll AJ, Heerema NA, Rubnitz JE, Loh ML, Raetz EA, Winick NJ, Hunger SP, Carroll WL, Gaynon PS, **Camitta BM**. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). *Blood*. 2007 Feb 01;109(3):926-35. PMID: PMC1785141
 207. Thompson PA, Murry DJ, Rosner GL, Lunagomez S, Blaney SM, Berg SL, **Camitta BM**, Dreyer ZE, Bomgaars LR. Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia. *Cancer Chemother Pharmacol*. 2007 May;59(6):847-53.
 208. Champlin RE, Perez WS, Passweg JR, Klein JP, **Camitta BM**, Gluckman E, Bredeson CN, Eapen M, Horowitz MM. Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. *Blood*. 2007 May 15;109(10):4582-5. PMID: PMC1885491
 209. Martin SB, Mosquera-Caro MP, Potter JW, Davidson GS, Andries E, Kang H, Helman P, Veroff RL, Atlas SR, Murphy M, Wang X, Ar K, Xu Y, Chen IM, Schultz FA, Wilson CS, Harvey R, Bedrick E, Shuster J, Carroll AJ, **Camitta B**, Willman CL. Gene expression overlap affects karyotype prediction in pediatric acute lymphoblastic leukemia. *Leukemia*. 2007 Jun;21(6):1341-4.
 210. Salzer WL, Devidas M, Shuster JJ, Wang C, Chauvenet A, Asselin BL, **Camitta BM**, Kurtzberg J, Children's Oncology Group. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group. *J Pediatr Hematol Oncol*. 2007 Jun;29(6):369-75.
 211. Cooley LD, Chenevert S, Shuster JJ, Johnston DA, Mahoney DH, Carroll AJ, Devidas M, Linda SB, Lauer SJ, **Camitta BM**. Prognostic significance of cytogenetically detected chromosome 21 anomalies in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. *Cancer Genet Cytogenet*. 2007 Jun;175(2):117-24.
 212. Heerema NA, Raimondi SC, Anderson JR, Biegel J, **Camitta BM**, Cooley LD, Gaynon PS, Hirsch B, Magenis RE, McGavran L, Patil S, Pettenati MJ, Pullen J, Rao K, Roulston D, Schneider NR, Shuster JJ, Sanger W, Sutcliffe MJ, van Tuinen P, Watson MS, Carroll AJ. Specific extra chromosomes occur in a modal number dependent pattern in pediatric acute lymphoblastic leukemia. *Genes Chromosomes Cancer*. 2007 Jul;46(7):684-93.
 213. Chauvenet AR, Martin PL, Devidas M, Linda SB, Bell BA, Kurtzberg J, Pullen J, Pettenati MJ, Carroll AJ, Shuster JJ, **Camitta B**. Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. *Blood*. 2007 Aug 15;110(4):1105-11. PMID: PMC1939894
 214. Nachman JB, Heerema NA, Sather H, **Camitta B**, Forestier E, Harrison CJ, Dastugue N, Schrappe M, Pui CH, Basso G, Silverman LB, Janka-Schaub GE. Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. *Blood*. 2007 Aug 15;110(4):1112-5. PMID: PMC1939895
 215. Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, **Camitta BM**, Champlin RE, Gale RP, Fuhrer M, Klein JP, Locasciulli A, Oneto R, Schattenberg AV, Socie G, Eapen M. Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. *Blood*. 2007 Aug 15;110(4):1397-400. PMID: PMC1939910
 216. Wacker P, Land VJ, **Camitta BM**, Kurtzberg J, Pullen J, Harris MB, Shuster JJ, Children's Oncology Study Group. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. *J Pediatr Hematol Oncol*. 2007 Sep;29(9):627-32.
 217. Eapen M, Zhang MJ, Devidas M, Raetz E, Barredo JC, Ritchey AK, Godder K, Grupp S, Lewis VA, Malloy K, Carroll WL, Davies SM, **Camitta BM**, Children's Oncology Group, Center for International Blood and Marrow Transplant Research. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. *Leukemia*. 2008 Feb;22(2):281-6.
 218. Dubowy R, Graham M, Hakami N, Kletzel M, Mahoney D, Newman E, Ravindranath Y, **Camitta B**. Sequential oral hydroxyurea and intravenous cytosine arabinoside in refractory childhood acute leukemia: a pediatric oncology group phase 1 study. *J Pediatr Hematol Oncol*. 2008 May;30(5):353-7. PMID: PMC4601800
 219. Rubnitz JE, Wichlan D, Devidas M, Shuster J, Linda SB, Kurtzberg J, Bell B, Hunger SP, Chauvenet A, Pui CH, **Camitta B**, Pullen J, Children's Oncology Group. Prospective analysis of TEL gene

- rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. *J Clin Oncol*. 2008 May 01;26(13):2186-91. PMID: PMC4485397
220. Gardner SL, Carreras J, Boudreau C, **Camitta BM**, Adams RH, Chen AR, Davies SM, Edwards JR, Grovas AC, Hale GA, Lazarus HM, Arora M, Stiff PJ, Eapen M. Myeloablative therapy with autologous stem cell rescue for patients with Ewing sarcoma. *Bone Marrow Transplant*. 2008 May;41(10):867-72. PMID: PMC3164955
221. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ, Viswanatha D, Willman CL, Winick N, **Camitta BM**, Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. *Blood*. 2008 Jun 15;111(12):5477-85. PMID: PMC2424148
222. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, **Camitta BM**, Gaynon PS, Carroll WL. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. *J Clin Oncol*. 2008 Aug 20;26(24):3971-8. PMID: PMC2654313
223. Bunin NJ, Davies SM, Aplenc R, **Camitta BM**, DeSantes KB, Goyal RK, Kapoor N, Kernan NA, Rosenthal J, Smith FO, Eapen M. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. *J Clin Oncol*. 2008 Sep 10;26(26):4326-32. PMID: PMC2653120
224. Drinker LR, Camitta MG, Herlong JR, Miller S, Lodge AJ, Jagers J, Barker PC. Use of the monoplane intracardiac imaging probe in high-risk infants during congenital heart surgery. *Echocardiography*. 2008 Oct;25(9):999-1003.
225. Pasquini R, Carreras J, Pasquini MC, **Camitta BM**, Fasth AL, Hale GA, Harris RE, Marsh JC, Robinson AJ, Zhang MJ, Eapen M, Wagner JE. HLA-matched sibling hematopoietic stem cell transplantation for fanconi anemia: comparison of irradiation and nonirradiation containing conditioning regimens. *Biol Blood Marrow Transplant*. 2008 Oct;14(10):1141-1147. PMID: PMC2581414
226. Yang JJ, Cheng C, Yang W, Pei D, Cao X, Fan Y, Pounds SB, Neale G, Treviño LR, French D, Campana D, Downing JR, Evans WE, Pui CH, Devidas M, Bowman WP, **Camitta BM**, Willman CL, Davies SM, Borowitz MJ, Carroll WL, Hunger SP, Relling MV. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. *JAMA*. 2009 Jan 28;301(4):393-403. PMID: PMC2664534
227. Horan JT, Carreras J, Tarima S, **Camitta BM**, Gale RP, Hale GA, Hinterberger W, Marsh J, Passweg JR, Walters MC, Eapen M. Risk factors affecting outcome of second HLA-matched sibling donor transplantations for graft failure in severe acquired aplastic anemia. *Biol Blood Marrow Transplant*. 2009 May;15(5):626-31. PMID: PMC2692140
228. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Wang C, Davies SM, Gaynon PS, Trigg M, Rutledge R, Burden L, Jorstad D, Carroll A, Heerema NA, Winick N, Borowitz MJ, Hunger SP, Carroll WL, **Camitta B**. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. *J Clin Oncol*. 2009 Nov 01;27(31):5175-81. PMID: PMC2773475
229. Salzer WL, Devidas M, Carroll WL, Winick N, Pullen J, Hunger SP, **Camitta BA**. Long-term results of the pediatric oncology group studies for childhood acute lymphoblastic leukemia 1984-2001: a report from the children's oncology group. *Leukemia*. 2010 Feb;24(2):355-70. PMID: PMC4300959
230. Gross TG, Hale GA, He W, **Camitta BM**, Sanders JE, Cairo MS, Hayashi RJ, Termuhlen AM, Zhang MJ, Davies SM, Eapen M. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. *Biol Blood Marrow Transplant*. 2010 Feb;16(2):223-30. PMID: PMC2911354
231. Kang H, Chen IM, Wilson CS, Bedrick EJ, Harvey RC, Atlas SR, Devidas M, Mullighan CG, Wang X, Murphy M, Ar K, Wharton W, Borowitz MJ, Bowman WP, Bhojwani D, Carroll WL, **Camitta BM**, Reaman GH, Smith MA, Downing JR, Hunger SP, Willman CL. Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. *Blood*. 2010 Feb 18;115(7):1394-405. PMID: PMC2826761
232. Litzow MR, Tarima S, Pérez WS, Bolwell BJ, Cairo MS, **Camitta BM**, Cutler CS, de Lima M, Dipersio JF, Gale RP, Keating A, Lazarus HM, Luger S, Marks DI, Maziarz RT, McCarthy PL, Pasquini MC, Phillips GL, Rizzo JD, Sierra J, Tallman MS, Weisdorf DJ. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. *Blood*. 2010 Mar 04;115(9):1850-7.

PMCID: PMC2832815

233. Mitchell ME, McManus M, Dietz J, **Camitta BM**, Szabo S, Havens P. Absidia corymbifera endocarditis: survival after treatment of disseminated mucormycosis with radical resection of tricuspid valve and right ventricular free wall. *J Thorac Cardiovasc Surg*. 2010 Apr;139(4):e71-2.
234. Stiff PJ, Agovi MA, Antman KH, Blaise D, **Camitta BM**, Cairo MS, Childs RW, Edwards JR, Gale RP, Hale GA, Lazarus HM, Arora M. High-dose chemotherapy with blood or bone marrow transplants for rhabdomyosarcoma. *Biol Blood Marrow Transplant*. 2010 Apr;16(4):525-32. PMCID: PMC2838953
235. Harvey RC, Mullighan CG, Chen IM, Wharton W, Mikhail FM, Carroll AJ, Kang H, Liu W, Dobbin KK, Smith MA, Carroll WL, Devidas M, Bowman WP, **Camitta BM**, Reaman GH, Hunger SP, Downing JR, Willman CL. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. *Blood*. 2010 Jul 01;115(26):5312-21. PMCID: PMC2902132
236. Marsh J, Socie G, Tichelli A, Schrezenmeier H, Hochsmann B, Risitano AM, Fuehrer M, Bekassy AN, Korthof ET, Locasciulli A, Ljungman P, Bacigalupo A, **Camitta B**, Young NS, Passweg J, European Group for Blood and Marrow Transplantation (EBMT) Severe Aplastic Anaemia Working Party. Should irradiated blood products be given routinely to all patients with aplastic anaemia undergoing immunosuppressive therapy with antithymocyte globulin (ATG)? A survey from the European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. *Br J Haematol*. 2010 Aug;150(3):377-9. PMCID: PMC3521531
237. Duval M, Klein JP, He W, Cahn JY, Cairo M, **Camitta BM**, Kamble R, Copelan E, de Lima M, Gupta V, Keating A, Lazarus HM, Litzow MR, Marks DI, Maziarz RT, Rizzieri DA, Schiller G, Schultz KR, Tallman MS, Weisdorf D. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. *J Clin Oncol*. 2010 Aug 10;28(23):3730-8. PMCID: PMC2917308
238. Maloney KW, Carroll WL, Carroll AJ, Devidas M, Borowitz MJ, Martin PL, Pullen J, Whitlock JA, Willman CL, Winick NJ, **Camitta BM**, Hunger SP. Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group. *Blood*. 2010 Aug 19;116(7):1045-50. PMCID: PMC2938126
239. Schultz KR, Prestidge T, **Camitta B**. Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options. *Expert Rev Hematol*. 2010 Dec;3(6):731-42.
240. Harvey RC, Mullighan CG, Wang X, Dobbin KK, Davidson GS, Bedrick EJ, Chen IM, Atlas SR, Kang H, Ar K, Wilson CS, Wharton W, Murphy M, Devidas M, Carroll AJ, Borowitz MJ, Bowman WP, Downing JR, Relling M, Yang J, Bhojwani D, Carroll WL, **Camitta B**, Reaman GH, Smith M, Hunger SP, Willman CL. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. *Blood*. 2010 Dec 02;116(23):4874-84. PMCID: PMC3321747
241. Dreyer ZE, Dinndorf PA, **Camitta B**, Sather H, La MK, Devidas M, Hilden JM, Heerema NA, Sanders JE, McGlennen R, Willman CL, Carroll AJ, Behm F, Smith FO, Woods WG, Godder K, Reaman GH. Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. *J Clin Oncol*. 2011 Jan 10;29(2):214-22. PMCID: PMC3058277
242. Salzer WL, Winick NJ, Wacker P, Lu X, Devidas M, Shuster JJ, Mahoney DH, Lauer SJ, **Camitta BM**. Plasma methotrexate, red blood cell methotrexate, and red blood cell folate values and outcome in children with precursor B-acute lymphoblastic leukemia: a report from the Children's Oncology Group. *J Pediatr Hematol Oncol*. 2012 Jan;34(1):e1-7. PMCID: PMC3771527
243. Yang JJ, Cheng C, Devidas M, Cao X, Fan Y, Campana D, Yang W, Neale G, Cox NJ, Scheet P, Borowitz MJ, Winick NJ, Martin PL, Willman CL, Bowman WP, **Camitta BM**, Carroll A, Reaman GH, Carroll WL, Loh M, Hunger SP, Pui CH, Evans WE, Relling MV. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia. *Nat Genet*. 2011 Mar;43(3):237-41. PMCID: PMC3104508
244. Gupta S, Cogbill CH, Gheorghe G, Rao AR, Kumar S, Havens PL, **Camitta BM**, Warwick AB. Mycobacterium avium intracellulare infection coexistent with nodular lymphocyte predominant Hodgkin lymphoma involving the lung. *J Pediatr Hematol Oncol*. 2011 Apr;33(3):e127-31.
245. Chu R, Brazauskas R, Kan F, Bashey A, Bredeson C, **Camitta B**, Chiang KY, Frangoul H, Gale RP, Gee A, George B, Goldman FD, Gross TG, Gupta V, Hale GA, Isola L, Ispizua AU, Lazarus H, Marsh J, Russell J, Sabloff M, Waller EK, Eapen M. Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched

- sibling donors for patients with severe aplastic anemia. *Biol Blood Marrow Transplant*. 2011 Jul;17(7):1018-24. PMID: PMC3114180
246. Rangarajan HG, Grochowski D, Mulberry MF, Gheorghe G, **Camitta BM**, Talano JA. Treatment of recurrent CNS disease post-bone marrow transplant in familial HLH. *Pediatr Blood Cancer*. 2012 Jul 15;59(1):189-90.
247. Asselin BL, Devidas M, Wang C, Pullen J, Borowitz MJ, Hutchison R, Lipshultz SE, **Camitta BM**. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). *Blood*. 2011 Jul 28;118(4):874-83. PMID: PMC3292437
248. Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM, Artz AS, Gupta V, Savani BN, McCarthy PL, Cahn JY, Schouten HC, Finke J, Ball ED, Aljurf MD, Cutler CS, Rowe JM, Antin JH, Isola LM, Di Bartolomeo P, **Camitta BM**, Miller AM, Cairo MS, Stockerl-Goldstein K, Sierra J, Savoie ML, Halter J, Stiff PJ, Nabhan C, Jakubowski AA, Bunjes DW, Petersdorf EW, Devine SM, Maziarz RT, Bornhauser M, Lewis VA, Marks DI, Bredeson CN, Soiffer RJ, Weisdorf DJ. Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. *Biol Blood Marrow Transplant*. 2012 Feb;18(2):280-8. PMID: PMC3224672
249. Zhang J, Mullighan CG, Harvey RC, Wu G, Chen X, Edmonson M, Buetow KH, Carroll WL, Chen IM, Devidas M, Gerhard DS, Loh ML, Reaman GH, Relling MV, **Camitta BM**, Bowman WP, Smith MA, Willman CL, Downing JR, Hunger SP. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. *Blood*. 2011 Sep 15;118(11):3080-7. PMID: PMC3175785
250. Bowman WP, Larsen EL, Devidas M, Linda SB, Blach L, Carroll AJ, Carroll WL, Pullen DJ, Shuster J, Willman CL, Winick N, **Camitta BM**, Hunger SP, Borowitz MJ. Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906. *Pediatr Blood Cancer*. 2011 Oct;57(4):569-77. PMID: PMC3136564
251. Kurtzberg J, Asselin B, Bernstein M, Buchanan GR, Pollock BH, **Camitta BM**. Polyethylene Glycol-conjugated L-asparaginase versus native L-asparaginase in combination with standard agents for children with acute lymphoblastic leukemia in second bone marrow relapse: a Children's Oncology Group Study (POG 8866). *J Pediatr Hematol Oncol*. 2011 Dec;33(8):610-6. PMID: PMC3557823
252. Schrappe M, Hunger SP, Pui CH, Saha V, Gaynon PS, Baruchel A, Conter V, Otten J, Ohara A, Versluis AB, Escherich G, Heyman M, Silverman LB, Horibe K, Mann G, **Camitta BM**, Harbott J, Riehm H, Richards S, Devidas M, Zimmermann M. Outcomes after induction failure in childhood acute lymphoblastic leukemia. *N Engl J Med*. 2012 Apr 12;366(15):1371-81. PMID: PMC3374496
253. Hunger SP, Lu X, Devidas M, **Camitta BM**, Gaynon PS, Winick NJ, Reaman GH, Carroll WL. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. *J Clin Oncol*. 2012 May 10;30(14):1663-9. PMID: PMC3383113
254. Chen IM, Harvey RC, Mullighan CG, Gastier-Foster J, Wharton W, Kang H, Borowitz MJ, **Camitta BM**, Carroll AJ, Devidas M, Pullen DJ, Payne-Turner D, Tasian SK, Reshmi S, Cottrell CE, Reaman GH, Bowman WP, Carroll WL, Loh ML, Winick NJ, Hunger SP, Willman CL. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. *Blood*. 2012 Apr 12;119(15):3512-22. PMID: PMC3325039
255. Oliansky DM, **Camitta B**, Gaynon P, Nieder ML, Parsons SK, Pulsipher MA, Dillon H, Ratko TA, Wall D, McCarthy PL Jr, Hahn T, American Society for Blood and Marrow Transplantation. Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. *Biol Blood Marrow Transplant*. 2012 Apr;18(4):505-22.
256. **Camitta BM**, Casper JT *Testing J Exp Med*. 1968 Sep 1;128(3):399-414
257. **Camitta B**. Tribute to Bart Kamen. *J Pediatr Hematol Oncol*. 2012 Nov;34(8):585-8.
258. **Camitta BM**, Nathan DG: Anemia in adolescence. *Postgrad Med* 57:143 & 151, 1975.
259. Boxer LA, **Camitta BM**, Berenberg W, Fanning JP. Myelofibrosis myeloid metaplasia in childhood. *Pediatr*. 1975;55:861.
260. Ayas M, Saber W, Davies SM, Harris RE, Hale GA, Socie G, LeRademacher J, Thakar M, Deeg HJ, Al-Seraihy A, Battiwalla M, **Camitta BM**, Olsson R, Bajwa RS, Bonfim CM, Pasquini R, Macmillan ML, George B, Copelan EA, Wirk B, Al Jefri A, Fath AL, Guinan EC, Horn BN, Lewis VA, Slavin

- S, Stepensky P, Bierings M, Gale RP. Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. *J Clin Oncol*. 2013 May 01;31(13):1669-76. PMID: PMC3635221
261. Xu H, Yang W, Perez-Andreu V, Devidas M, Fan Y, Cheng C, Pei D, Scheet P, Burchard EG, Eng C, Huntsman S, Torgerson DG, Dean M, Winick NJ, Martin PL, **Camitta BM**, Bowman WP, Willman CL, Carroll WL, Mullighan CG, Bhojwani D, Hunger SP, Pui CH, Evans WE, Relling MV, Loh ML, Yang JJ. Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. *J Natl Cancer Inst*. 2013 May 15;105(10):733-42. PMID: PMC3691938
262. Hitzler JK, He W, Doyle J, Cairo M, **Camitta BM**, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, O'Brien T, Pulsipher MA, Smith FO, Zhang MJ, Eapen M, Carpenter PA, CIBMTR Pediatric Cancer Working Committee. Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. *Biol Blood Marrow Transplant*. 2013 Jun;19(6):893-7. PMID: PMC3707801
263. Keating A, DaSilva G, Pérez WS, Gupta V, Cutler CS, Ballen KK, Cairo MS, **Camitta BM**, Champlin RE, Gajewski JL, Lazarus HM, Lill M, Marks DI, Nabhan C, Schiller GJ, Socie G, Szer J, Tallman MS, Weisdorf DJ. Autologous blood cell transplantation versus HLA-identical sibling transplantation for acute myeloid leukemia in first complete remission: a registry study from the Center for International Blood and Marrow Transplantation Research. *Haematologica*. 2013 Feb;98(2):185-92. PMID: PMC3561424
264. Dunsmore KP, Devidas M, Linda SB, Borowitz MJ, Winick N, Hunger SP, Carroll WL, **Camitta BM**. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. *J Clin Oncol*. 2012 Aug 01;30(22):2753-9. PMID: PMC3402886
265. Zhang MJ, Davies SM, **Camitta BM**, Logan B, Tiedemann K, Eapen M, Thiel EL. Comparison of outcomes after HLA-matched sibling and unrelated donor transplantation for children with high-risk acute lymphoblastic leukemia. *Biol Blood Marrow Transplant*. 2012 Aug;18(8):1204-10. PMID: PMC3890239
266. Chang BH, Willis SG, Stork L, Hunger SP, Carroll WL, **Camitta BM**, Winick NJ, Druker BJ, Schultz KR. Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph+ ALL: a Children's Oncology Group (COG) study. *Br J Haematol*. 2012 May;157(4):507-10. PMID: PMC4290865
267. Xu H, Cheng C, Devidas M, Pei D, Fan Y, Yang W, Neale G, Scheet P, Burchard EG, Torgerson DG, Eng C, Dean M, Antillon F, Winick NJ, Martin PL, Willman CL, **Camitta BM**, Reaman GH, Carroll WL, Loh M, Evans WE, Pui CH, Hunger SP, Relling MV, Yang JJ. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia. *J Clin Oncol*. 2012 Mar 01;30(7):751-7. PMID: PMC3295551
268. Bunin NJ, Davies SM, Aplenc R, **Camitta BM**, DeSantes KB, Goyal RK, Kapoor N, Kernan NA, Rosenthal J, Smith FO, Eapen M. Unrelated donor bone marrow transplantation for children with acute myeloid leukemia beyond first remission or refractory to chemotherapy. *J Clin Oncol*. 2008 Sep 10;26(26):4326-32. PMID: PMC2653120
269. Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, **Camitta BM**, Gaynon PS, Carroll WL. Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. *J Clin Oncol*. 2008 Aug 20;26(24):3971-8. PMID: PMC2654313
270. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ, Viswanatha D, Willman CL, Winick N, **Camitta BM**, Children's Oncology Group. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. *Blood*. 2008 Jun 15;111(12):5477-85. PMID: PMC2424148
271. Foran JM, Pavletic SZ, Logan BR, Agovi-Johnson MA, Pérez WS, Bolwell BJ, Bornhäuser M, Bredeson CN, Cairo MS, **Camitta BM**, Copelan EA, Dehn J, Gale RP, George B, Gupta V, Hale GA, Lazarus HM, Litzow MR, Maharaj D, Marks DI, Martino R, Maziarz RT, Rowe JM, Rowlings PA, Savani BN, Savoie ML, Szer J, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research. *Biol Blood Marrow Transplant*. 2013 Jul;19(7):1102-8. PMID: PMC3691352
272. Lee SJ, Storer B, Wang H, Lazarus HM, Waller EK, Isola LM, Klumpp TR, Umejiego JB, Savani BN,

- Loren AW, Cairo MS, **Camitta BM**, Cutler CS, George B, Jean Khoury H, Marks DI, Rizzieri DA, Copelan EA, Gupta V, Liesveld JL, Litzow MR, Miller AM, Schouten HC, Gale RP, Cahn JY, Weisdorf DJ. Providing personalized prognostic information for adult leukemia survivors. *Biol Blood Marrow Transplant*. 2013 Nov;19(11):1600-7. PMID: PMC3832127
273. Rangarajan HG, Punzalan RC, **Camitta BM**, Talano JA. The use of novel Therakos™ Cellex® for extracorporeal photopheresis in treatment of graft-versus-host disease in paediatric patients. *Br J Haematol*. 2013 Nov;163(3):357-64.
274. Warlick ED, Paulson K, Brazauskas R, Zhong X, Miller AM, **Camitta BM**, George B, Savani BN, Ustun C, Marks DI, Waller EK, Baron F, Freytes CO, Socie G, Akpek G, Schouten HC, Lazarus HM, Horwitz EM, Koreth J, Cahn JY, Bornhauser M, Seftel M, Cairo MS, Laughlin MJ, Sabloff M, Ringdén O, Gale RP, Kamble RT, Vij R, Gergis U, Mathews V, Saber W, Chen YB, Liesveld JL, Cutler CS, Ghobadi A, Uy GL, Eapen M, Weisdorf DJ, Litzow MR. Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. *Biol Blood Marrow Transplant*. 2014 Feb;20(2):202-8. PMID: PMC3924751
275. Perez-Andreu V, Roberts KG, Harvey RC, Yang W, Cheng C, Pei D, Xu H, Gastier-Foster J, E S, Lim JY, Chen IM, Fan Y, Devidas M, Borowitz MJ, Smith C, Neale G, Burchard EG, Torgerson DG, Klussmann FA, Villagran CR, Winick NJ, **Camitta BM**, Raetz E, Wood B, Yue F, Carroll WL, Larsen E, Bowman WP, Loh ML, Dean M, Bhojwani D, Pui CH, Evans WE, Relling MV, Hunger SP, Willman CL, Mullighan CG, Yang JJ. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse. *Nat Genet*. 2013 Dec;45(12):1494-8. PMID: PMC4039076
276. Tower RL, Jones TL, **Camitta BM**, Asselin BL, Bell BA, Chauvenet A, Devidas M, Halperin EC, Pullen J, Shuster JJ, Winick N, Kurtzberg J. Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group. *J Pediatr Hematol Oncol*. 2014 Jul;36(5):353-61. PMID: PMC4120865
277. Hitzler JK, He W, Doyle J, Cairo M, **Camitta BM**, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, O'Brien T, Pulsipher MA, Smith FO, Zhang MJ, Eapen M, Carpenter PA, CIBMTR Pediatric Cancer Working Committee. Outcome of transplantation for acute lymphoblastic leukemia in children with Down syndrome. *Pediatr Blood Cancer*. 2014 Jun;61(6):1126-8. PMID: PMC4080799
278. Ayas M, Eapen M, Le-Rademacher J, Carreras J, Abdel-Azim H, Alter BP, Anderlini P, Battiwalla M, Bierings M, Buchbinder DK, Bonfim C, **Camitta BM**, Fasth AL, Gale RP, Lee MA, Lund TC, Myers KC, Olsson RF, Page KM, Prestidge TD, Radhi M, Shah AJ, Schultz KR, Wirk B, Wagner JE, Deeg HJ. Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure. *Biol Blood Marrow Transplant*. 2015 Oct;21(10):1790-5. PMID: PMC4568139
279. Mehta PA, Zhang MJ, Eapen M, He W, Seber A, Gibson B, **Camitta BM**, Kitko CL, Dvorak CC, Nemecek ER, Frangoul HA, Abdel-Azim H, Kasow KA, Lehmann L, Gonzalez Vicent M, Diaz Pérez MA, Ayas M, Qayed M, Carpenter PA, Jodele S, Lund TC, Leung WH, Davies SM. Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia. *Biol Blood Marrow Transplant*. 2015 Jul;21(7):1273-7. PMID: PMC4465998
280. Dreyer ZE, Hilden JM, Jones TL, Devidas M, Winick NJ, Willman CL, Harvey RC, Chen IM, Behm FG, Pullen J, Wood BL, Carroll AJ, Heerema NA, Felix CA, Robinson B, Reaman GH, Salzer WL, Hunger SP, Carroll WL, **Camitta BM**. Intensified chemotherapy without SCT in infant ALL: results from COG P9407 (Cohort 3). *Pediatr Blood Cancer*. 2015 Mar;62(3):419-26. PMID: PMC5145261
281. Asselin BL, Devidas M, Chen L, Franco VI, Pullen J, Borowitz MJ, Hutchison RE, Ravindranath Y, Armenian SH, **Camitta BM**, Lipshultz SE. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. *J Clin Oncol*. 2016 Mar 10;34(8):854-62. PMID: PMC4872007
282. Khandelwal P, Millard HR, Thiel E, Abdel-Azim H, Abraham AA, Auletta JJ, Boulad F, Brown VI, **Camitta BM**, Chan KW, Chaudhury S, Cowan MJ, Angel-Diaz M, Gadalla SM, Gale RP, Hale G, Kasow KA, Keating AK, Kitko CL, MacMillan ML, Olsson RF, Page KM, Seber A, Smith AR, Warwick AB, Wirk B, Mehta PA. Hematopoietic Stem Cell Transplantation Activity in Pediatric Cancer between 2008 and 2014 in the United States: A Center for International Blood and Marrow

- Transplant Research Report. *Biol Blood Marrow Transplant*. 2017 Aug;23(8):1342-1349. PMID: PMC5669065
283. Winick N, Martin PL, Devidas M, Shuster J, Borowitz MJ, Paul Bowman W, Larsen E, Pullen J, Carroll A, Willman C, Hunger SP, Carroll WL, **Camitta BM**. Randomized assessment of delayed intensification and two methods for parenteral methotrexate delivery in childhood B-ALL: Children's Oncology Group Studies P9904 and P9905. *Leukemia*. 2020 Apr;34(4):1006-1016. PMID: PMC7749787
284. Khauv P, Sreynich K, Lyvannak S, **Camitta BM**. Pyrites: An Episcleral Mass. *J Pediatr Hematol Oncol*. 2021 Jul 01;43(5):200.
285. Lyvannak S, Sreynich K, Heng S, Nara L, Farrilend P, **Camitta BM**. Pyrites: A Perineal Mass. *J Pediatr Hematol Oncol*. 2021 Jul 01;43(5):201-202.

Books, Chapters, and Reviews

1. **Camitta BM**. The current status of histocompatible bone marrow transplantation for severe aplastic anemia. In: *Topics in Hematology Proceedings of the 16th International Congress of Hematology*. Excerpta Medica, Amsterdam 1978.
2. **Camitta BM**. Histocompatible bone marrow transplantation for hereditary and acquired marrow aplasias in children. In: Japan Medical Research Foundation (ed). *Aplastic Anemia*. Tokyo University Press, Tokyo, 1978.
3. **Camitta BM**. Childhood anaemia. *American Academy Family Physicians Monograph* 12, June 1978.
4. **Camitta BM**. The role of viral infections in aplastic anemia. In: Heimpel H, Gordon Smith EC, Heit W, Kubanek B (eds). *Aplastic Anemia, Pathophysiology and Approaches to Therapy*. Springer Verlag, Berlin, 1979.
5. **Camitta BM**. Pathogenesis of aplastic anemia: Inferences from therapeutic trials. In: Heimpel H, Gordon Smith EC, Heit W, Kubanek B (eds). *Aplastic Anemia, Pathophysiology and Approaches to Therapy*. Springer Verlag, Berlin, 1979.
6. **Camitta BM**. Aplastic and hypoplastic anemias. In: Kelley VC (ed). *Practice of Pediatrics*. Harper Row, Hagerstown, 1980.
7. **Camitta BM**. A prospective study of the effect of androgens on severe aplastic anemia. In: Najean Y (ed.). *Medullary Aplasia*. Masson, New York, 1980.
8. Ross J, Maquat LE, Kinniburgh AJ, Beach LR, **Camitta BM**, Honig GR, Lazerson J, Ershler WB. Beta thalassemia syndromes: Mutations that result in inefficient processing of the beta globin mRNA precursor. In: Goldwasser E (ed). *The Regulation of Hemoglobin Biosynthesis*. Elsevier, North Holland, 1983.
9. Margolis DA, **Camitta B**. Clinical correlation of glucocorticoid receptor content in childhood acute lymphoblastic leukemia. In: Gametchu B, ed. *Glucocorticoid Receptor Structure and Leukemic Cell Responses*. New York, NY: Springer-Verlag; 1995: 155-162.

Abstracts

1. **Camitta BM**, Forman E, Parkman R, Rapoport J, Orellana T, Nathan D: Aplastic Anemia (AA) following hepatitis - An indication for early bone marrow transplantation. *Pediatr Res*. 1973;7:61
2. Levine MD, **Camitta BM**, Nathan DG, Curran WJ. Medical ethics of bone marrow transplantation in childhood. *Pediatr Res*. 1974;8:471
3. **Camitta BM**, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC. Severe aplastic anemia: An indication for marrow transplantation. *Blood*. 1975;46:1001
4. Propper R, **Camitta BM**, Jaffe N, Traggis P, Sallan S. Increased adriamycin (A) cardiotoxicity in leukemic children. *Pediatr Res*. 1975;9:391
5. Sallan S, **Camitta BM**, Chess L. Improved remission duration in childhood acute lymphoblastic leukemia with mediastinal mass. *Proc Am Soc Clin Oncol*. 1976;19:298
6. Holcenberg JS, **Camitta BM**. Delayed leucovorin rescue after high dose methotrexate. *Proc Am Assoc Cancer Res*. 1977;18:180
7. Holcenberg JS, **Camitta BM**, Borella LD. Human pharmacology of succinylated acinetobacter glutaminase-asparaginase. *Clin Res*. 1977;25:611
8. Rapoport J, Parkman R, **Camitta B**, Levey RL, Nathan DG. Successful bone marrow transplantation of pre-sensitized recipients with severe aplastic anemia (AA) after multi-agent immunosuppression (MAI). *Blood*. 1977;50:315a
9. **Camitta B**, Thomas D, Nathan D, Santos G, Gordon-Smith E, Rapoport J. Severe aplastic anemia: Effect of

- androgens on survival. *Blood*. 1977;50:313a
10. Holcenberg JS, **Camitta BM**, Borella LD, Ring B. Phase I study of succinylated acinetobacter glutaminase-asparaginase. *Proc Am Assoc Cancer Res*. 1978;19:229
 11. **Camitta B**, Pinkel D, Thatcher LG, Casper J. Failure of early intensified therapy to improve prognosis in childhood acute lymphocytic leukemia. *Blood*. 1978;52:242a
 12. Weinstein HJ, Mayer RJ, Rosenthal DS, **Camitta BM**, Nathan DG, Frei E III. Sequential combination chemotherapy (SCC) for remission prolongation in acute myelogenous leukemia (AML). *Blood*. 1978;52:280a
 13. Lauer S, Borella L, **Camitta B**. Phenotype shifts in childhood leukemia/ lymphoma. *Proc Am Assoc Cancer Res*. 1979;20:268
 14. Weinstein HJ, Mayer RJ, Rosenthal DS, **Camitta BM**. Childhood and adult acute myelogenous leukemia (AML): Prolonged unmaintained remission after intensive sequential combination chemotherapy (SCC). *Proc Am Soc Clin Oncol*. 1978;20:327
 15. Casper JT, **Camitta B**, Hodach A, Altman A, von Hoff D. The soft-agar cloning technique for human neuroblastoma: Potential for clinical studies. *Proc Am Assoc Cancer Res*. 1980;21:168
 16. Lauer S, Casper J, **Camitta B**. Heterogeneity in pediatric T-cell leukemia/lymphoma. *Proc Am Assoc Cancer Res*. 1981;21:184
 17. Kun L, **Camitta B**, Kaplan B, Lauer S, Mulhern R. Management of post-irradiation meningeal leukemia (ML) in childhood acute lymphoblastic leukemia (ALL). *Proc Am Soc Clin Oncol*. 1981;21:485
 18. Sheth KJ, **Camitta BM**. Renal involvement in Fanconi's Anemia. *Pediatric Res*. 1981;15:699
 19. Lauer S, Casper J, Keller R, Kirchner P, **Camitta B**. The use of counter-flow centrifugation-elutriation for separation of bone marrow lymphoid cells in children with acute lymphocytic leukemia (ALL) and metastatic solid tumors. *Blood*. 1981;58:84a
 20. Weinstein HJ, Coral FS, **Camitta BM**, Gelber RD, Frei E III. Treatment of acute myelogenous leukemia (AML) in children. *Pediatric Res*. 1982;16:218A
 21. Weinstein HJ, Mayer RJ, Rosenthal DS, Coral FS, Gelber RD, **Camitta BM**, Nathan DG, Frei E III. Acute myelogenous leukemia (AML) in children and adults: Followup. *Proc Am Soc Clin Oncol*. 1982;1:125
 22. Harb JM, Werlin SL, **Camitta B**: Hepatic ultrastructure in methotrexate treated childhood leukemias. *Gastroenterology*. 1982;82:1230
 23. **Camitta B**, O'Reilly RJ, Sensenbrenner L, Rapoport J, Champlin R, Doney K, August C. Severe aplastic anemia: A controlled trial of antilymphocyte globulin therapy. *Blood*. 1982;60:165a
 24. **Camitta BM**. Immunosuppressive therapy and aplastic anemia - ATG. Presented at the UCLA symposium on Recent Advances in Bone Marrow Transplantation, Park City, 1983. *J Cellular Biochem*. 1983;(Suppl 7A):43
 25. Kien CL, **Camitta BM**. Accelerated energy and protein metabolism in children with newly-diagnosed acute lymphoblastic leukemia. *Pediatric Res*. 1983;17:192A
 26. Kun L, **Camitta B**, Mulhern R, Lauer S, Casper J, Kaplan B. Treatment of meningeal relapse in childhood acute lymphoblastic leukemia (ALL): Results of craniospinal irradiation. *Proc Am Soc Clin Oncol*. 1983;2:78
 27. Lauer S, **Camitta B**, Sartain P, Buchanan G, Pinkel D, Krance R, Borella L. Cytosine arabinoside/cyclophosphamide pulses improve prognosis in childhood T-cell acute lymphocytic leukemia (ALL). *Proc Am Soc Clin Oncol*. 1983;2:77
 28. Rivera G, Buchanan GR, Crist WM, **Camitta BM**, Simone JV. Intensive retreatment of relapsed acute lymphocytic leukemia (ALL) of childhood. *Proc Am Soc Clin Oncol*. 1983;2:174
 29. Abrams R, Polacek L, Hansen R, Casper J, **Camitta B**, Anderson T. Variable precryopreservation recovery of CFU-6M following ficoll-hypaque (FH) processing of autologous bone marrow collections (ABMC). *Blood*. 1983;62:216a
 30. Grier H, **Camitta B**, Link M, Coral F, Gelber R, Delorey M, Weinstein H. A seven-year experience with intensive post-remission chemotherapy for childhood acute myelogenous leukemia (AML). *Blood*. 1983;62:203a
 31. Rivera G, Buchanan GR, Crist WM, **Camitta BM**. Influence of intensive periodic reinduction therapy throughout second marrow remission for childhood acute lymphocytic leukemia. *Proc Am Assoc Cancer Res*. 1984;25:187
 32. Gelber R, Grier H, Price K, **Camitta B**, Link M, Coral F, Delorey M, Weinstein H. Prognostic factors for acute myelogenous leukemia (AML). *Proc Am Soc Clin Oncol*. 1984;3:196
 33. Ash RC, Serwint MS, Coffey C, Greenwood M, Geil J, Romond E, **Camitta B**, McDonald J, Thompson J,

- Maruyama Y. Allogeneic marrow transplantation for leukemic patients who lack matched sibling donors, utilizing partially matched related donors in concert with T-cell depletion for graft vs host disease (GVHD) prophylaxis. *Blood*. 1985;66:264a
34. Kien CL, **Camitta BM**. Elevated rates of whole body protein synthesis and breakdown are closely associated with neutrophil and lymphocyte counts in children with acute lymphocytic leukemia. *J Parenteral Enteral Nutrition*. 1986;10:3S
 35. **Camitta B**, Lauer S, Casper J, Adair S, Kamen B, Kun L. Intensive alternating drug pairs for treatment of high-risk childhood acute lymphocytic leukemia. *Proc Am Soc Clin Oncol*. 1986;5:150
 36. Ash RC, Casper J, Serwint MS, Coffey C, Bruckman JE, Greenwood M, Geil J, Romond E, **Camitta B**, McDonald J, Thompson J, Muruyama Y. Allogeneic marrow transplantation for leukemic patients who lack matched sibling donors, utilizing partially matched related donors in concert with T-cell depletion for GvHD prophylaxis. *Proc Am Soc Clin Oncol*. 1986;5:159
 37. Graham-Pole J, Gross S, **Camitta B**, Casper J, Herzig R, Norris D, Koch P, Steuber P, Boyett J, Marcus R, Munoz L, Elfenbein G, Weiner R. Bone marrow transplantation (BMT) for acute lymphoblastic leukemia (ALL): Impact of conditioning with cytosine arabinoside (araC) and fractionated total body irradiation (fTBI) on subsequent relapse (rel): A Pediatric Oncology Group (POG) pilot. *Proc Am Assoc Cancer Res*. 1986;27:206
 38. Ash RC, Menitove J, Casper J, Chitambar C, Hansen R, Anderson T, **Camitta B**, Eckels D, Truitt R, Hunter J, Aster R. Unrelated donor marrow transplantation: Apparent benefits of T-depletion with post-transplant cyclosporin (CSA) for GVHD prophylaxis. *Exp Hematol*. 1987;15:592
 39. Grier H, Delorey M, **Camitta B**, Link M, Blattner S, Perrine S, Weinstein H. Acute myelogenous leukemia in infants. *Proc Am Soc Clin Oncol*. 1987;6:154
 40. Ash RC, Menitove J, Casper J, Chitambar C, Hansen R, Bratanow N, Lum L, Anderson T, Bunin N, **Camitta B**, Truitt R, Hunter J, Aster R. Successful allogeneic marrow transplantation utilizing HLA-closely matched unrelated donors. *Blood*. 1987;70:289a
 41. Casper J, Bunin N, Hunter J, Murray K, Lum L, Truitt R, Menitove J, Aster R, **Camitta B**, Ash R. Unrelated bone marrow transplantation in children. *J Cell Biochem*. 1988;(Suppl 12c):97
 42. **Camitta B**, Casper JT, Hunter J, Bunin N, Menitove J, Lum L, Ash R. Alternative bone marrow donors for children with aplastic anemia. *J Cell Biochem*. 1988;(Suppl 12c):97
 43. Lauer S, **Camitta B**, Graham M, Leventhal B, Casper J, Civin C, Adair S. Early intensive rotating therapy for higher risk childhood acute lymphocytic leukemia (CALL): A Pediatric Oncology Group (POG) pilot study. *Proc Am Soc Clin Oncol*. 1988;7:179
 44. **Camitta B**, Lauer S, Graham M, Leventhal B, Civin C, Casper J, Adair S. Early intensive methotrexate (MTX)/6 mercaptopurine (6MP) for lower risk childhood acute lymphocytic leukemia (ALL): A Pediatric Oncology Group (POG) pilot study. *Proc Am Soc Clin Oncol*. 1988;7:174
 45. Bunin NJ, Casper JT, Chitambar C, Hunter J, Truitt R, Menitove J, **Camitta B**, Ash R. Partially matched bone marrow transplantation (BMT) using T-cell depletion in patients with myelodysplastic syndromes (MDS). *Proc Am Soc Clin Oncol*. 1988;7:175
 46. Wyatt DT, Lum LG, Casper J, Hunter J, **Camitta BM**. Autoimmune thyroiditis after bone marrow transplant. *Pediatr Res*. 1988;23:350a
 47. Sheth KJ, Segura AD, Bunin NJ, **Camitta BM**, Ash RC, Casper JT. Renal involvement in partially matched bone marrow transplantation (BMT). *Pediatr Res*. 1988;23:546a
 48. Ash RC, Casper J, Menitove J, Chitambar C, Hansen R, Lum L, Anderson T, **Camitta B**, Truitt RT, Hunter J, Aster R. Successful allogeneic marrow transplantation utilizing HLA-closely matched unrelated donors. *Blood*. 1988;72:378a
 49. Casper J, Bunin N, Hunter J, Murray K, Lawton C, Menitove J, Lum L, Truitt R, **Camitta B**, Ash R. The successful use of unrelated donors for twenty-three pediatric bone marrow transplants. *Blood*. 1988;72:382a
 50. Graham-Pole J, **Camitta B**, Casper J, Elfenbein G, Gross S, Herzig R, Koch P, Mahoney D, Marcus R, Munoz L, Pick T, Spruce W, Steuber P, Weiner R. Marrow transplantation (BMT) for patients (PTS) with acute lymphoblastic leukemia (ALL): Reducing relapses and toxicity (TOX) post-BMT. *Exp Hematol*. 1988;16:345
 51. **Camitta B**, Wells R, Dunn D, Flatley T, Segura A, Oechler H. Response of osteoid osteoma to chemotherapy. *Proc Am Soc Clin Oncol*. 1989;8:301
 52. Steuber CP, Holbrook T, **Camitta B**, Land VJ, Sexauer C, Krischer J. Toxicity trials of Amsacrine (AMSA), VPI6, +/- Azacytidine (AZ) in childhood non-lymphocytic leukemia (ANLL) - A pilot study. *Proc Am*

- Soc Clin Oncol. 1989;30:263
53. Casper J, Hunter J, Baxter-Lowe L, Murray K, Lawton C, Menitove J, Lum L, Truitt R, **Camitta B**, Ash R. The successful use of unrelated donors for fifty-five bone marrow transplants. *Exp Hematol*. 1989;17:706
 54. Ash RC, Casper J, Lawton C, Hansen R, Chitambar C, Murray K, **Camitta B**, Anderson T, Truitt R. "Third generation" T depletion GVHD prophylaxis in genotypically HLA-matched sibling marrow transplantation: Durable engraftment with apparent preservation of the graft-versus-leukemia (GVL) effect. *Blood*. 1989;74:122a
 55. Ash RC, Casper J, Hansen R, Chitambar C, Baxter-Lowe LA, Hunter J, Lawton C, Murray K, Truitt R, **Camitta B**, Anderson T, Menitove J. Successful marrow transplantation from closely HLA-matched unrelated donors. *Blood*. 1989;74:163a
 56. **Camitta B**, Casper JT, Hunter J, Menitove J, Ash R. Alternative bone marrow donors for children with aplastic anemia. *J Cell Biochem*. 1990;(Suppl 14a):283
 57. Casper J, Bunin N, Hunter J, Baxter-Lowe LA, Murray K, Lawton C, Menitove J, Truitt R, **Camitta B**, Ash R. Unrelated donors for pediatric bone marrow transplantation. *J Cell Biochem*. 1990;(Suppl 14a):326
 58. Casper J, Bunin N, Hunter J, Baxter-Lowe LA, Murray K, Lawton C, Truitt R, **Camitta B**, Ash R. Unrelated donors for bone marrow transplantation in children with leukemia. *Proc Am Soc Clin Oncol*. 1991;10:238
 59. Casper J, Baxter-Lowe LA, Truitt R, Murray K, Lawton C, Bunin N, Hunter J, **Camitta B**, Ash R. Unrelated donors for bone marrow transplantation in children. *J Cell Biochem*. 1992;(Suppl 16A):208
 60. Ravindranath Y, Yeager A, Krischer J, Steuber CP, Graham-Pole J, **Camitta B**, Weinstein H. Intensive consolidation chemotherapy (ICC) vs purged autologous bone marrow transplantation (ABMT) early in remission for treatment of childhood acute myeloid leukemia (AML): Preliminary results of Pediatric Oncology Group (POG) study 8821. *Proc Am Soc Clin Oncol*. 1992;11:280
 61. Casper J, **Camitta B**, Ash R, Bunin N, Pietryga D, Garbrecht F, Baxter-Lowe LA, Murray K, Lawton C, Truitt R, Keever C, Flomenberg N. Bone marrow transplantation for Philadelphia chromosome positive (Ph+) acute lymphocytic leukemia (ALL) using alternative donors. *Blood*. 1992;80:65a
 62. Drobyski WR, Ash RC, Casper JT, McAuliffe T, Horowitz MM, Lawton C, Keever C, Baxter-Lowe LA, **Camitta B**, Garbrecht F, Pietryga D, Hansen R, Chitambar C, Anderson T, Flomenberg N. Impact of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease-free survival in unrelated marrow transplantation for chronic myelogenous leukemia. *Blood*. 1993;82:423a
 63. Casper J, **Camitta B**, Baxter-Lowe LA, Bunin N, Ash R, Pietryga D, Garbrecht F, Murray K, Lawton C, Truitt R, Keever C, Flomenberg N. Bone marrow transplantation (BMT) for childhood acute lymphocytic leukemia (ALL) using unrelated donors. *Blood*. 1993;82:170a
 64. Kawanishi Y, Flomenberg N, Gray A, Drobyski W, Horowitz M, Casper J, **Camitta B**, Pietryga D, Garbrecht F, Keever CA. Effect of T-cell subset content in acute graft vs. host disease following T-cell depleted bone marrow transplantation. *Blood*. 1993;82:423a
 65. Baxter-Lowe LA, Casper J, Flomenberg N, Dinauer D, **Camitta B**, Drobyski W, Garbrecht F, Pietryga D, Anderson T, Chitambar C, Hansen R, Lawton C, Bunin N, Keever C, Pierce K, Ash R. Impact of HLA disparity in bone marrow transplantation. *J Immunol*. 1993;150(8):part 2
 66. **Camitta B**, Casper J, Pietryga D, Garbrecht F, Ash R, Keever C, Murray K, Baxter-Lowe L, Flomenberg N. Unrelated donor bone marrow transplantation (BMT) for children with severe aplastic anemia. *Blood*. 1993;82:344a
 67. Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen E, Drobyski W, Horowitz M, **Camitta B**, Garbrecht F, Pietryga D, Lawton C, Ash R, Gottschall J. Therapeutic plasma exchange not effective in the management of TTP/HUS following bone marrow transplantation. *Blood*. 1993;82:419a
 68. Pietryga D, **Camitta B**, Casper J, Garbrecht F, Ash R, Bunin N, Keever C, Murray K, Baxter-Lowe LA, Flomenberg N. T-cell depleted bone marrow transplantation (BMT) for Wiskott-Aldrich syndrome (WAS) using unrelated donors. *J Cell Biochem*. 1994;(Suppl 18B):72
 69. Casper J, **Camitta B**, Baxter-Lowe LA, Bunin N, Ash R, Pietryga D, Garbrecht F, Murray K, Lawton C, Truitt R, Keever C, Flomenberg N. Bone marrow transplantation (BMT) for childhood acute lymphocytic leukemia (ALL) using unrelated donors. *J Cell Biochem*. 1994;(Suppl 18B):70
 70. **Camitta B**, Casper J, Pietryga D, Garbrecht F, Ash R, Keever C, Murray K, Baxter-Lowe LA, Flomenberg N. Bone marrow transplantation (BMT) for aplastic anemia (AA) using unrelated donors. *J Cell Biochem*. 1994;(Suppl 18B):69
 71. Ravindranath Y, Yeager A, Krischer J, Steuber CP, Graham-Pole J, **Camitta B**, Weinstein H. Intensive

- consolidation chemotherapy (ICC) vs purged autologous bone marrow transplantation (ABMT) early in remission for treatment of childhood acute myeloid leukemia (AML): Preliminary results of Pediatric Oncology Group (POG) study 8821. *Proc Am Soc Clin Oncol*. 1994;13:320
72. Lauer S, Shuster J, Kirchner P, Kiefer G, Pullen J, **Camitta B**, Land V. Prognostic significance of cerebrospinal fluid (CSF) lymphoblasts (LB) at diagnosis (dx) in children with acute lymphoblastic leukemia (ALL). *Proc Am Soc Clin Oncol*. 1994;13:317
73. Steuber P, Holbrook T, **Camitta B**, Land V, Sexauer C, Weinstein H, Krisher J. Induction treatment of refractory or recurrent childhood AML using amasacrine and etoposide with or without 5-azacitidine: A phase II Pediatric Oncology Group study. *Proc Am Soc Clin Oncol*. 1994;13:318
74. Whitehead VM, Vuchich M-J, Carroll AJ, Lauer SJ, Mahoney D, Shuster JJ, Payment C, Koch PA, Akabutu JJ, Bowen T, Kamen BA, Ravindranath Y, Emami A, Beardsley GP, Pullen DJ, **Camitta B**. Relation of methotrexate polyglutamate (MTXPG) accumulation in lymphoblasts to trisomy of both chromosomes 4 and 10 and to ploidy in childhood acute lymphoblastic leukemia (ALL): A Pediatric Oncology Group study. *Blood*. 1994;84:515a
75. Pietryga D, Casper J, Garbrecht F, **Camitta B**, Drobyski W, Horowitz M, Lawton C, Keever C, Baxter-Lowe L, Murray K, Pierce K, Cadwallader S, McAuliffe T, Flomenberg N. Haploidentical bone marrow transplantation (BMT) for hematologic malignancies. *Blood*. 1994;84:339a
76. Keever CA, Kawanishi Y, Wank T, Chaltry M, Craig A, Drobyski W, Horowitz M, Casper J, **Camitta B**, Pietryga D, Garbrecht F, Flomenberg N, Baxter-Lowe LA. Correlation of T-cell dose and CTL precursor frequency with graft versus host disease and survival after unrelated or partially matched related BMT. *Blood*. 1994;84:99a
77. Guinan E, Lopez K, McKenzie S, Lobel J, Cohen P, Singer D, McIntosh S, **Camitta B**, Kurtzberg J. Successful treatment (Rx) of patients (pts) with refractory severe aplastic anemia (SAA) with concomitant cyclosporine (CSA) and colony stimulating factors (CSF). *Blood*. 1994;84:10a
78. Ravindranath Y, Chang M, **Camitta B**, Steuber CP, Carroll A, Gresik MV, Raimondi S, Weinstein H. Prognostic factor in childhood acute myeloid leukemia (AML). Experience on Pediatric Oncology Group (POG) 8821 AML study. *Blood*. 1994;86:599a
79. Kletzel M, Morgan E, Cohn S, Williams L, **Camitta B**. Autologous bone marrow (BM)/peripheral blood stem cells (PBSC) rescue in children with relapsed Wilms tumor (WT). *Med Pediatr Oncol*. 1994;23:167-217
80. Mahmoud H, Schwartz C, Shuster J, Pui CH, Behm F, Amylon M, Raimondi S, Borowitz M, Link M, Pullen J, **Camitta B**, Hakami N, Crist W, Carroll A. The (11;19) translocation is associated with poor outcome in infants with acute lymphoblastic leukemia: A collaborative study of the POG and SJCRH. *Med Pediatr Oncol*. 1994;23:167-217
81. Yeager AM, Ravindranath Y, Krisher J, Steuber CP, Ogden A, Graham-Pole J, **Camitta B**, Weinstein H. Chemopurged autologous bone marrow transplantation (ABMT) versus intensive consolidation chemotherapy (ICC) for acute myeloid leukemia (AML) in children: Pediatric Oncology Group (POG) study 8821. Proceedings of the Seventh International Autologous BMT Symposium, Arlington, 1994
82. Lauer SJ, Toledano S, Winick NB, Munoz L, Mahoney D, Pullen J, Steuber CP, Shuster J, **Camitta B**. A comparison of early intensive methotrexate/mercaptopurine (MTX/MP) vs early intensive alternating chemotherapy for high risk acute lymphoblastic leukemia (HR-ALL). A Pediatric Oncology Group (POG) randomized phase III study. *Proc Am Soc Clin Oncol*. 1995;14:342
83. Borowitz MJ, Shuster J, Carroll AJ, Look AT, **Camitta B**, Mahoney D, Lauer S, Pullen DJ. Prognostic significance of antigen fluorescence intensity (FI) in B-precursor acute lymphocytic leukemia in (ALL): Early outcome data from the Pediatric Oncology Group. *Blood*. 1995;86:41a
84. Juckett M, Rowlings P, Drobyski W, Horowitz M, Lawton C, Keever C, Pietryga D, Casper J, **Camitta B**, Margolis D, Hanson G. T-cell depleted allogeneic bone marrow transplant for non-Hodgkins lymphoma: A single institution experience in 32 patients. *Blood*. 1995;86:210a
85. Ravindranath Y, Chang M, Gresik V, Yeager A, Steuber CP, Carroll A, Raimondi S, **Camitta B**, Weinstein H. Intensive consolidation chemotherapy (ICT) vs autologous bone marrow transplantation (ABMT) in first remission of childhood AML: Experience on Pediatric Oncology Group study POG 8821. *Medical and Pediatric Oncology*. 1995;25:283-332
86. Whitehead VM, Vuchich M-J, Carroll A, Lauer S, Mahoney D, Shuster J, Payment C, Bernstein M, Akabutu J, Bowen T, Kamen B, Ravindranath Y, Emami A, Beardsley P, Pullen J, **Camitta B**. Translocations involving chromosome 12p, methotrexate metabolism and outcome in childhood B-progenitor cell acute lymphoblastic leukemias (ALL): A Pediatric Oncology Group pharmacology pilot study. *Proc Am Assoc Cancer Res* 1996;37:381

87. Behm FG, Carroll A, Shuster J, **Camitta B**, Link M, Lauer S, Land V, Steuber P, Crist W, Pullen J. MLL-rearrangement predicts a high risk of failure in children ≥ 1 year of age with precursor-B ALL. *Proc Am Assoc Cancer Res.* 1996;37:186
88. Dreyer ZE, Steuber CP, Bowman WP, Murray JC, Dinndorf P, **Camitta B**. Induction intensification for infant acute lymphoid leukemia (ALL). *Proc Am Soc Clin Oncol.* 1996;15:369
89. Drobyski WR, Horowitz M, Pietryga D, Margolis D, Juckett M, Burns W, **Camitta B**, Rowlings P, Keever-Taylor C, Casper J. Unrelated donor marrow transplantation for acute myelogenous leukemia (AML), myelodysplasia, and secondary AML. *Blood.* 1996;88:269a
90. Pietryga D, Casper J, Margolis D, **Camitta B**, Garbrecht F, Drobyski W, Horowitz M, Burns W, Juckett M, Rowlings P, Passweg J, Lawton C, Taylor C, Baxter-Lowe L, Murray K, Pierce K, McAuliffe J, Flomenberg N. Bone marrow transplantation (BMT) using genotypically haploidentical donors. *Blood.* 1996;88:264a
91. Rubnitz JE, Shuster JJ, Land VJ, Link MP, Pullen DJ, **Camitta B**, Pui C-H, Downing JR, Behm FG. Case-control study of children with acute lymphoblastic leukemia confirms the favorable impact of TEL gene rearrangements: A Pediatric Oncology Group study. *Blood.* 1996;88:450a
92. Abish S, Carroll A, Shuster J, **Camitta B**, Pullen J. A comparison of the balanced and unbalanced 1;19 translocation in childhood acute lymphoblastic leukemia (ALL): a Pediatric Oncology Group study. *Blood.* 1997;90:185a
93. Hunger SP, Fall MZ, **Camitta BM**, Carroll AJ, Link MP, Lauer SJ, Mahoney DH, Pullen DJ, Shuster JJ, Steuber CP, Cleary ML. EZA-PBX1 chimeric transcript at end of consolidation is not predictive of treatment outcomes in childhood acute lymphoblastic leukemias (ALLs) with a t(1;19)(q23; p13): a Pediatric Oncology Group (POG) study. *Blood.* 1997;90:423a
94. Bell B, Abish S, Shuster J, **Camitta B**. Neurotoxicity (NT) in patients with standard risk acute lymphoblastic leukemia (ALL) on Pediatric Oncology Group (POG) 9405: a preliminary report. *Blood.* 1997;90:559a
95. Borowitz MJ, Rubnitz J, Nash M, Pullen DJ, **Camitta B**. Predictability of the TEL-AML1 rearrangement from surface antigen phenotype in childhood B-precursor ALL. A Pediatric Oncology Group study. *Blood.* 1997;90:210b
96. Margolis D, Pietryga D, **Camitta B**, Keever-Taylor C, Lawton C, Murray K, Garbrecht F, Casper J. Unrelated donor bone marrow transplantation for childhood AML: an update of the Milwaukee experience. *Blood.* 1997;90:397b
97. Baxter-Lowe LA, Parrish R, Margolis D, Szmania S, Seuryneck K, White J, Wank T, Molter M, Hazlett L, Drobyski W, Garbrecht F, Pietryga D, Horowitz M, **Camitta B**, Vesole D, Burns W, Flomenberg N, Casper J, Keever-Taylor C. HLA disparity detected by automated nucleotide sequencing may aid in selection of alternative donors. *Blood.* 1997;90:109a
98. Pietryga D, Mahmoud HH, Margolis DA, Rock AL, **Camitta B**, Casper JT. VP16/2 CDA therapeutic window pre-bone marrow transplant conditioning regimen for children with relapsed or refractory leukemia. *Med Pediatr Oncol.* 1996;27:209-374
99. Passweg JR, Schrezenmeier H, **Camitta B**, Socie G, Hows J, Rowling PA, Horowitz MN. Alternative donor bone marrow transplantation for patients with severe aplastic anemia. *Blood.* 1997;90:106a
100. Whitehead VM, Payment C, Vuchich M-J, Cooley L, Lauer SJ, Mahoney DH, Shuster JJ, Bernstein ML, Kamen BA, Look AT, Pullen DJ, **Camitta B**. The TEL-AML1 translocation and methotrexate polyglutamate (MTXPG) levels in childhood B-progenitor cell acute lymphoblastic leukemia (pro-BALL): a Pediatric Oncology Group study. *Proc Am Assoc Cancer Res.* 1998;39:329
101. Dreyer ZE, Steuber CP, Bowman WP, Murray JC, Coppes MJ, Dinndorf P, **Camitta B**. High risk infant ALL - improved survival with intensive chemotherapy. *Proc Am Soc Clin Oncol.* 1998;17:529a
102. Griffin TC, Shuster JJ, Buchanan GR, Wharam SB, Murphy SB, **Camitta B**, Amylon M. Slow reduction of peripheral blood blast count in an adverse prognostic factor in childhood T-cell acute lymphoblastic leukemia (T-ALL): a Pediatric Oncology Group study. *Proc Am Soc Clin Oncol.* 1998;17:527a
103. Weir E, Carroll A, Pullen J, Head D, **Camitta B**, Thomas P, McIntyre B, Borowitz M. True mixed lineage leukemia is a rare disease with poor outcome. *Blood.* 1998;92:398a
104. Kaleem Z, Shuster JJ, Carroll AJ, Borowitz MJ, Pullen DJ, **Camitta BM**, Zutter MM, Watson MS. Acute lymphoblastic leukemia with t(8;14)(q11;q32). *Blood.* 1998;92:398a
105. Li P, Shuster JJ, Pullen DJ, Borowitz MJ, **Camitta BM**, Carroll AJ. RT-PCR detection of TEL/AML 1 and AML 1/TEL chimeric transcripts in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. *Blood.* 1998;92:392a
106. Pui C-H, Wiley JM, Woods GM, Hastings C, Leverger G, **Camitta B**, Blaney SM, Grabicki JM, Czerniak

- RM, Harvey E, Mahmoud HH, Relling MV, Reaman GH. Recombinant urate oxidase corrects hyperuricemia in patients treated for leukemia or lymphoma. *Blood*. 1998;92:482a
107. Rubnitz JE, **Camitta BM**, Raimondi SC, Carroll AJ, Borowitz MJ, Shuster JJ, Link MP, Pullen DJ, Downing JR, Behm FG, Mahmoud H, Pui C-H. Childhood acute lymphoblastic leukemia with the MLL-ENL fusion and t(11;19)(q23;p13.3). Favorable prognosis in T-cell cases. *Blood*. 1998;92:312a
108. Wacker P, Shuster JJ, Pullen J, Humbert J, Land VJ, Mahoney DH, Lauer SJ, Look AT, Borowitz MJ, Carroll AJ, **Camitta BM**. Interaction amongst gender, prognostic factors, and time in children with B-precursor ALL: a pediatric Oncology Group study. *Med Pediatr Oncol*. 1998;31
109. Kung FH, Bernstein ML, **Camitta BM**, Harris MB, Vietti TJ, Sullivan J. Ifosfamide/carboplatin/etoposide (ICE) in the treatment of advanced recurrent Wilms tumor. *Proc Am Soc Clin Oncol*. 1999;18:559a
110. Laver JH, Barredo JC, Amylon M, Kurtzberg J, **Camitta BM**, Pullen J, Link M, Ravindranath Y, Murphy SB, Shuster J. Effects of cranial radiation in children with high risk T-cell acute lymphoblastic leukemia. *Proc Am Soc Clin Oncol*. 1999;18:565a
111. Warwick AB, Zhang MJ, **Camitta BM**, Shuster JJ, Horowitz MM. Chemotherapy versus HLA-identical sibling bone marrow transplantation for childhood acute lymphoblastic leukemia (ALL) in first remission. *Blood*. 1999;94:350a
112. Arico M, Valsecchi MG, **Camitta B**, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui C-H, Masera G. Heterogeneity of treatment outcome in children with Philadelphia chromosome positive acute lymphoblastic leukemia: A collaborative study of 326 patients. *Blood*. 1999;94:695a
113. Wacker P, Land VJ, **Camitta BM**, Kurtzberg J, Pullen J, Shuster JJ. Allergy to E. Coli (Ec) L-asparaginase (ASP) has no significant correlation with prognosis of childhood B-precursor ALL. A Pediatric Oncology Group (POG) study. *Pediatr Blood Cancer*. 1999;33(3)
114. Ravindranath Y, Chang M, Raimondi SC, Carroll A, Steuber CP, **Camitta B**, Weinstein H. Prognostic factors in childhood acute myeloid leukemia (AML): analysis of children treated on Pediatric Oncology Group (POG) study 8821. *Ann Hematol*. 1999;78 Suppl 2:S1-53
115. Pui C-H, Jeha S, **Camitta B**. Recombinant urate oxidase (Rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia: the compassionate use experience. *Blood*. 2000;96
116. Litzow M, Bolwell B, **Camitta B**, Copelan E, Gale R, Giralt S, Keating A, Klein J, Lazarus H, Marks D, McCarthy P, Miller C, Perez W, Prentice HG, Russell J, Schultz K, Trigg M, Weisdorf, Horowitz M. Comparison of allogeneic bone marrow transplantation (BMT) with cyclophosphamide-total body irradiation (CyTBI) versus busulfan-cyclophosphamide (BuCy) conditioning regimens for acute myelogenous leukemia (AML) in first remission. *Blood*. 2000;96:480a
117. Harbott J, Heerema N, Baruchel A, **Camitta B**, Chessells JM, Gaynon PS, Janka-Schaub G, Pui C-H, Sallan SE, Schrappe M, Valsecchi MG, Arico M. Secondary chromosomal aberrations in 255 childhood cases of Ph-positive acute lymphoblastic leukemia (ALL). *Blood*. 2000;96
118. Viswanatha D, Bartolo C, Chem I-M, **Camitta B**, Pullen J, Willman CL, Borowitz M. Comparison of polymerase chain reaction (PCR) and flow cytometry (FC) for the detection of minimal residual disease (MRD) in pediatric acute lymphoblastic leukemia (ALL): a Pediatric Oncology Group study. *Blood*. 2000;96:314a
119. Asselin B, Shuster J, Amylon M, Halperin E, Hutchison R, Lipshultz S, **Camitta B**. Improved event-free survival with high dose methotrexate (HDM) in T-cell lymphoblastic leukemia (T-ALL) and advanced lymphoblastic lymphoma (T-NHL): a Pediatric Oncology Group study. *Proc Am Soc Clin Oncol*. 2001;20:367a
120. Wacker P, Winick N, Shuster JJ, Mahoney DH, Lauer S, Kamen BA, **Camitta BM**. Lack of significant correlation between plasma methotrexate (MTX), red blood cells (RBC) MTX and RBC folate levels with EFS in children with B-precursor ALL. A Pediatric Oncology Group study. *Blood*. 2001;98:113a
121. Fernandes C, Leclerc GJ, Altman-Hamandzic S, Shuster J, Pullen J, **Camitta B**, Safa AR, Barredo J. Quantitative expression of multidrug resistance related protein (MRP1) and lung resistance protein (LRP) by real-time RT-PCR does not predict treatment outcome and survival in children with T-lineage acute lymphoblastic leukemia. *Blood*. 2001;98:318a
122. Blanco JG, Edick MJ, Shuster JJ, Dervieux T, Amylon MD, Bash RO, Behm FG, **Camitta BM**, Pui C-H, Raimondi S, Winick NJ, Hancock ML. Genetic polymorphisms in NQO1 and CYP3A4 in children with treatment-related acute myeloid malignancies. *Blood*. 2001;98:323a
123. Godder K, Eapen M, Laver J, **Camitta B**, Horowitz MM. Autologous stem cell transplantation (SCT) for acute myeloid leukemia (AML) in 1st or 2nd complete remission (CR)- prognostic factor analysis. *Blood*. 2001;98:688a

124. Borowitz MJ, Shuster J, Viswanatha DS, Willman CS, Montgomery K, Pullen J, Carroll AJ, **Camitta B**. Correlation of end-induction minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) with clinical and biological risk factors. A Children's Oncology Group study. *Blood*. 2001;98:841a
125. Mosquera-Caro M, Potter J, Andries E, Martin S, Hellman P, Veroff R, Kang H, Wang X, **Camitta B**, Shuster J, Carroll A, Murphy M, Schultz F, Wilson C, Dahl G, Arceci R, Haaland D, Davidson G, Atlas S, Willman C. Gene expression profiling for molecular classification and outcome prediction in infant leukemia reveals novel biologic clusters, etiologies and pathways for treatment failure. *Blood*. 2002;100:139a
126. Heerema N, Shuster J, Biegel J, **Camitta B**, Cooley LD, Hirsch B, Magen HE, Patil S, Pettanati M, Pullen J, Raimondi SC, Rao K, Schneider NR, Roulston D, Sanger W, Sather HN, Sutcliffe MJ, vanTuijn P, Watson MS, Carroll AJ. Pattern of extra chromosomes in pediatric hyperdiploid (50 to 67 chromosomes) acute lymphoblastic leukemia (ALL) is modal number (mn) dependent. *Blood*. 2002;100:308a
127. Pui C-H, Jeha S, Irwin D, Shen V, Shenoy S, Blaney S, **Camitta B**. Recombinant urate oxidase (Rasburicase, Elitek) for prevention and treatment of malignancy-associated hyperuricemia: updated results of a compassionate use trial. *Blood*. 2002;100:556a
128. Mosquera-Caro M, Potter J, Kand H, Andries E, Hellman P, Veroff R, Carroll A, Raimondi S, Shuster J, **Camitta B**, Arceci R, Dahl G, Davidson G, Atlas S, Willman C. Heterogeneity of gene expression profiles in MLL-associated infant leukemia: identification of distinct expression profiles and novel therapeutic targets for each MLL translocation variant. *Blood*. 2002;100:744a
129. Viswanatha D, Mosquera-Caro M, Potter J, Wilson C, Ar K, Xu Y, Harvey R, Hellman P, Verhoff B, Davidson G, Shuster J, Carroll A, **Camitta B**, Atlas S, Willman C. Gene expression profiling of pediatric acute lymphoblastic leukemia reveals unique subgroups independent of current genetic risk stratification. *Blood*. 2002;100:753a
130. Talano JM, Margolis DA, **Camitta BM**, Keever-Taylor CA, Murray KJ, Eapen M, Pierce KL, Casper JT. Outcome of unrelated and haploidentical bone marrow transplants in children with Philadelphia chromosome positive acute lymphoblastic leukemia Ph+ ALL). *Blood*. 2002;100:855a
131. Barredo JC, Lauer S, Billet A, Marymount MA, Devidas M, **Camitta B**, Winick N, Carroll W, Ritchey AK. Isolated CNS relapse of acute lymphoblastic leukemia (ALL) treated with intensive systemic chemotherapy and delayed CNS radiation: a Pediatric Oncology Group study. *Proc Am Soc Clin Oncol*. 2003;22:796
132. Mosquera-Caro MP, Helman P, Veroff R, Shuster J, Martin SB, Davidson GS, Potter JW, Harvey R, Hromas R, Andries E, Atlas S, Wilson CS, Ar K, Xu Y, Chen I-M, Carroll A, **Camitta B**, Willman CL. Identification, validation, and cloning of a novel gene (OPAL1) and associated genes highly predictive of outcome in pediatric acute lymphoblastic leukemia using gene expression profiling. *Blood*. 2003;102:4a
133. Schrezenmeier H, Bredeson C, Bruno B, Loberiza FR, **Camitta B**, oneto R, Socie G, Bacigalupo A, Pasquini R, Pasweg J, Marsh J. Comparison of allogeneic bone marrow and peripheral blood stem cell transplantation for aplastic anemia: collaborative study of European Blood and Marrow Transplant Group (EGBMT) and International Bone Marrow Transplant Registry (IBMTR). *Blood*. 2003;102:79a
134. Champlin RE, Perez WS, Passeg J, Klein JP, **Camitta BM**, Gluckman E, Bredeson C, Horowitz MM. Addition of antithymocyte globulin (ATG) to cyclophosphamide (Cy) for HLA-identical bone marrow transplantation (BMT) for severe aplastic anemia (SAA): results of a randomized controlled trial. *Blood*. 2003;102:80a
135. Eapen M, Horowitz MM, Klein JP, Zhang M-J, **Camitta BM**, Kurtzberg J, Davies SM, Ortega JJ, Wagner JE. Comparable long-term survival after unrelated donor bone marrow or umbilical cord blood and HLA-sibling transplants for treatment of acute leukemia in infants. *Blood*. 2003;102:245a
136. Hull KJ, Bell BB, Chauvenet AR, Kurtzberg J, Sterikoff S, Devidas M, **Camitta B**. Utility of end consolidation bone marrow aspirates in childhood acute lymphoblastic leukemia [ALL]: a Pediatric Oncology Group study. *Proc Am Soc Clin Oncol*. 2004;23:811a
137. Matloub J, Asselin BL, Stork LC, Devidas M, Sather H, Nachman J, Seibel N, Carroll W, **Camitta B**, Gaynon PS. Outcome of children with T-cell Acute Lymphoblastic Leukemia (T-ALL) and standard risk features: results of CCG-1952, CCG-1991 and POG 9404. *Blood*. 2004;104:195a
138. Schultz KR, Pullen J, Sather H, Shuster J, Borowitz MJ, Heerema N, Carroll AJ, Gaynon PS, **Camitta BM**. Biology-driven classification of childhood acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).

- Blood. 2004;104:151a
139. Seibel NL, Asselin BL, Nachman JB, Steinherz P, **Camitta B**, Devidas M, Sather HN. Treatment of high risk T-cell acute lymphoblastic leukemia (T-ALL): comparison of recent experience of the Children's Cancer Group (CCG) and Pediatric Oncology Group (POG). *Blood*. 2004;104:195a
 140. Chesley R, Bell BA, Devidas M, Bostrom B, Erdmann G, Sterikoff S, **Camitta B**. A comparison of hepatotoxicity and neutropenia in children given oral mercaptopurine on a twice-daily versus once-daily dosing schedule for acute lymphoblastic leukemia: a Pediatric Oncology Group study. *Blood*. 2004;104:284a
 141. Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, **Camitta B**. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood ALL: implications for residual disease (MRD) detection. *Blood*. 2004;104:310a
 142. Chauvenet A, Martin P, Bell B, Kurtzburg J, Pullen J, Shuster J, Devidas M, Linda S, **Camitta B**. Anti-Metabolite Therapy for Lesser-Risk B-Lineage Acute Lymphoblastic Leukemia of Childhood: Pediatric Oncology Group (POG) Study 9201. *Pediatr Blood Cancer*. 2005;567(abstract 1717)
 143. Chauvenet A, Martin P, Bell B, Kurtzburg J, Pullen J, Shuster J, Devidas M, Linda S, **Camitta B**. Anti-Metabolite Therapy for Lesser-Risk B-Lineage Acute Lymphoblastic Leukemia of Childhood: Pediatric Oncology Group (POG) Study 9201. *Pediatr Blood Cancer*. 2005;45:421, Abstract O.148
 144. Eapen M, Zhang M-J, Raetz E, Devidas M, Carroll WL, Ritchey AK, Barredo JC, Godder K, Grupp SA, Lewis VA, Davies S, **Camitta B**. Outcomes after HLA-matched sibling transplants or chemotherapy in children with acute lymphoblastic leukemia in a second remission after an isolated central nervous system relapse. *Blood*. 2006;108:19a
 145. Rubnitz J, Wichlan D, Devidas M, Shuster J, Kurtzburg J, Bell B, Hunger S, Chauvenet A, Pui C-H, **Camitta B**, Pullen J. Prospective analysis of TEL and MLL rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. *Blood*. 2006;108:68a
 146. Borowitz MJ, Devidas M, Bowman WP, Carroll WL, Chen I-M, Harvey R, Hunger S, Martin PL, Pullen J, Viswanatha D, Willman CL, Winick N, **Camitta B**. Prognostic significance of minimal residual disease (MRD) in childhood B-precursor ALL and its relation to other risk factors. A Children's oncology group (COG) study. *Blood*. 2006;188(69a)
 147. Harrison M, Bell B, Chauvenet A, Kurtzburg J, **Camitta B**, Devidas M. Testicular relapse in lesser, standard, and high risk patients treated with frontline therapy for childhood ALL. Pediatric Oncology Group protocols 9201, 9405, 9605, and 9406. *Blood*. 2006;108:528a
 148. Dunsmore K, Devidas M, Borowitz MJ, Winick N, Hunger S, Carroll WL, **Camitta B**. Nelarabine can be safely incorporated into an intensive, multiagent chemotherapy regimen for the treatment of T-cell acute lymphoblastic leukemia (ALL) in children: a report of the Children's Oncology Group (COG) AALL00P2 protocol for T-cell leukemia. *Blood*. 2006;108:528a
 149. Raetz EA, Borowitz MJ, Devidas M, Hunger SP, Winick N, **Camitta B**, Gaynon PS, Carroll WL. Outcomes of children with first marrow relapse: results from Children's Oncology Group (COG) study AALL01P2. *Blood*. 2006;108:530a
 150. Winick N, Borowitz MJ, Devidas M, Martin PL, Pullen J, Hunger SP, Carroll WL, **Camitta B**. Changes in the delivery of standard chemotherapeutic agents during induction affect early measures of minimal residual disease (MRD): POG 9900 for patients with B-precursor low and standard risk ALL. *Blood*. 2006;108:643a
 151. Schrappe M, Baruchel A, Pui C-H, Sallan S, **Camitta B**, Masera G, Zimmerman M. Non-responders to induction therapy in childhood ALL: an intergroup meta-analysis. *Pediatr Blood Cancer*. 2006;47(Suppl 6)
 152. Talano J-A, **Camitta B**, Keever-Taylor C, Anderson L, Wallach C, Casper J, Margolis D. Long term outcomes of unrelated donor bone marrow transplantation in children with severe aplastic anemia: an update of the Milwaukee experience. *Blood*. 2006;108:3128a
 153. Dreyer Z, Dinndorf P, Sather H, Steuber P, Carroll W, Hilden J, Shuster J, Dunn N, Oblendar M, **Camitta B**. Induction intensification in infant ALL modifies traditional risk factors: a Pediatric Oncology Group study. *Pediatr Blood Cancer*. 2006;47(Suppl 6):381(abstract O.096)
 154. Dreyer ZE, Dinndorf P, Sather H, Hilden JM, Devidas M, Heerema NA, Smith FO, Carroll W, Reaman G, **Camitta B**. Hematopoietic stem cell transplant (HSCT) versus intensive chemotherapy in infant acute lymphoblastic leukemia (ALL). *Proc Am Soc Clin Oncol*. 2007;25:529s
 155. Schultz KR, Bowman WP, Slayton W, Aledo A, Devidas M, Sather H, Borowitz MJ, Davies SM, Trigg M, Pasut B, Jorstad D, Eslinger T, Burden LE, Wang C, Rutledge R, Gaynon PS, Carroll AJ, Heerema NA, Winick N, Hunger S, Carroll WL, **Camitta B**. Improved early event free survival (EFS) in

- children with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with intensive imatinib in combination with high dose chemotherapy: Children's Oncology Group (COG) study AALL0031. *Blood*. 2007;110:9a
156. Winick N, Martin PL, Devidas M, Shuster J, Borowitz MJ, Bowman P, Larsen E, Pullen J, Hunger SP, Carroll WL, **Camitta BM**. Delayed intensification (DI) enhances event-free survival (EFS) of children with B-precursor acute lymphoblastic leukemia (ALL) who received intensification therapy with six courses of intravenous methotrexate (MTX): a Children's Oncology Group study (COG). *Blood*. 2007;110:179a
157. Gaynon PS, **Camitta BC**, Matlouyb Y, Martin PL, Winick N, Seibel NL, Bowman WP, Sather H, Devidas M, Hunger S, Carroll WL. Outcomes for B-precursor patients in legacy Children's Cancer Group (CCG) and Pediatric Oncology Group (POG) studies in childhood acute lymphoblastic leukemia (ALL): a Children's Oncology Group (COG) report. *Blood*. 2007;110:260a
158. Carson TY, Bell BA, Erdmann G, Bostrom B, **Camitta BM**, Devidas M. Possible advantage of twice-daily 6-mercaptopurine dosing in children with acute lymphoblastic leukemia (ALL). *Blood*. 2007;110:261a
159. Horan J, Carreras J, Tarima S, **Camitta B**, Gale RP, Hintergerger W, Marsh J, Pasquini R, Pasquini M, Walters M, Eapen M. Risk factors and outcome after second HLA-matched sibling donor transplantation for graft failure after a first HLA-matched sibling transplant in severe aplastic anemia. *Blood*. 2007;110:337a
160. Kang H, Bedrick EJ, Chen I-M, Wilson CS, Atlas SR, Harvey RC, Hunger SP, Devidas M, Borowitz MJ, Bowman P, Carroll Wl, **Camitta B**, Willman CL. Molecular classifiers for prediction of minimal residual disease (MRD) and event free survival (EFS) improve risk assignment at diagnosis in pediatric high-risk B precursor acute lymphoblastic leukemia (ALL): a Children's Oncology Group study. *Blood*. 2007;110:426a
161. Harvey RC, Davidson GS, Wand X, Dobbin KK, Bedrick EJ, Wilson CS, Atlas SR, Kang H, Chen I-M, Hunger SP, Devidas M, Carroll WL, Bowman P, **Camitta B**, Reaman G, Willman CL. Expression profiling identifies novel genetic subgroups with distinct clinical features and outcomes in high-risk pediatric precursor B acute lymphoblastic leukemia (B-ALL). A Children's Oncology Group study. *Blood*. 2007;110:428a
162. Hale GA, He V, Termuhlen AM, Davies SM, **Camitta BM**, Cairo MS, Eapen M, Gross TG. Outcomes after hematopoietic stem cell transplant (HSCT) for non-Hodgkin lymphoma (NHL) in children and adolescents. *Biol Blood Marrow Transplant*. 2008;14:24
163. Borowitz MJ, Devidas M, Hunger SP, Carroll WL, Linda S, Pullen DJ, Viswanatha D, Willman CL, Winick N, **Camitta BM**. Prognostic significance of end consolidation minimal residual disease (MRD) in childhood acute lymphoblastic leukemia (ALL). *Proc Am Soc Clin Oncol*. 2008;26:539s
164. Dunsmore K, Devidas M, Borowitz MJ, Winick N, Hunger SP, Carroll WL, **Camitta BM**. Nelarabine in combination with intensive modified BFM AALL00P2: A pilot study for the treatment of high risk T-ALL: a report from the Children's Oncology Group. *Proc Am Soc Clin Oncol*. 2008;26:539s
165. Maloney K, Carroll WL, Devidas M, Hunger SP, Martin PL, Willman CL, Winick N, Whitlock J, **Camitta BM**. Comparison of the biology of Down syndrome (DS) acute lymphoblastic leukemia (ALL) and non-DS ALL: Children's Oncology Group (COG) study P9900. *Proc Am Soc Clin Oncol*. 2008; 26:539s
166. Schultz KR, Bowman WP, Slayton W, Aledo A, Devidas M, Sather H, Borowitz MJ, Davies SM, Trigg M, Pasut B, Jorstad D, Eslinger T, Burden L, Wang C, Rutledge R **Camitta B**, Gaynon PS, Carroll AJ, Heerema NA, Winick N, Hunger SP, Carroll WL. Philadelphia chromosome negative (Ph-) very high risk (VHR) acute lymphoblastic leukemia (ALL) in children and adolescents: the impact of intensified chemotherapy on early event free survival (EFS) in Children's Oncology Group (COG) study AALL0031. *Blood*. 2008;112:337a
167. Gross Tg, Hale GA, Wensheng HE, **Camitta BM**, Sanders JE, Cairo MS, Hayashi RJ, Termuhlen AM, Zhang M-J, Davies SM, Eapen M. Hematopoietic stem cell transplantation (HSCT) as salvage for non-Hodgkin lymphoma NHL) in children and adolescents: a report from the Center for International Blood and Marrow Transplant Research. *Hematology Meeting Reports*. 2009; 3(5):55
168. Robinson BW, Devidas M, Carroll AJ, Harvey RC, Heerema NA, Willman CL, Hudome AR, Woods EC, Ballantyne NC, Reaman GH, Hilden JM, **Camitta BM**, Winick NJ, Carroll WL, Hunger SP, Dreyer ZE, Felix CA. Specific partner genes in infant acute lymphoblastic leukemia (ALL) associated with outcome are linked to age and white blood cell count (WBC) at diagnosis: a report on the Children's Oncology Group (COG) P9407 trial. *Blood*. 2009;114:374a
169. Chen L, Bell B, Waller J, Hall P, Devidas M, Lukacik M, **Camitta B**. Hepatotoxicity in standard risk B-cell

- precursor pediatric acute lymphoblastic leukemia patients treated on Pediatric Oncology Group (POG) protocol 9605. *Blood*. 2009;114:802a
170. Carroll AJ, Heerema NA, Devidas M, Bowman WP, Wang C, Trigg M, **Camitta B**, Gaynon PS, Winick NJ, Hunger SP, Carroll WL, Schultz KR. Secondary chromosomal abnormalities appear to be less prognostic for children with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL) treated with intensive imatinib and chemotherapy: results of the Children's Oncology Group (COG) study AALL0031. *Blood*. 2009;114:1022a
171. Chang BH, Willis SG, Stork LC, Hunger SP, Carroll WL, **Camitta B**, Winick NJ, Druker BJ, Schultz KR. Mutational analysis of BCR-Abl from subjects with relapsed Ph+ ALL treated on the COG protocol AALL0031: a report from the Children's Oncology Group. *Blood*. 2009;114:1033a
172. Schultz KR, Bowman WP, Aledo A, Slayton WB, Sather H, Devidas M, Wang C, Davies SM, Gaynon PS, Trigg M, Rutledge R, Burden L, Jorstad D, Carroll A, Heerema N, Winick N, Borowitz M, Hunger SP, Carroll WL, **Camitta B**. Continuous dosing Imatinib with intensive chemotherapy gives equivalent outcomes to allogeneic BMT for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) with longer term follow up: updated results of the Children's Oncology Group (COG) AALL0031. *Pediatric Blood Cancer*. 2010;54:788
173. Yang J, Xu H, Cheng C, Devidas M, Pei D, Fan Y, Yang W, Neale GA, Winick MJ, Martin PL, Willman CL, **Camitta BM**, Reaman GH, Carroll WL, Loh M, Hunger SP, Evans WE, Relling MV. ARID5B genetic polymorphisms contribute to racial disparities in childhood acute lymphoblastic leukemia: a Children's Oncology Group study. *Blood*. 2010;116:9a
174. Kang H, Wilson CS, Harvey RC, Chen I-M, Murphy MH, Atlas SR, Bedrick EJ, Devidas M, Carroll AJ, Robinson BW, Heerema NA, Hilden JM, Dreyer ZE, **Camitta B**, Winick N, Carroll WL, Felix CA, Reaman GH, Hunger SP, Willman CL. Gene expression profiling reveals genes predictive of outcome in infant acute lymphoblastic leukemia (ALL) and distinctive age-related gene expression profiles (< 90 days vs. > 90 days): a Children's Oncology Group study. *Blood*. 2010;116:183a
175. Armand P, Perez W, Zhang M-J, Kim H, Klumpp TR, Cin PD, Waller EK, Litzow MR, Liesveld JL, Lazarus HM, Artz A, Gupta V, Savani BN, McCarthy PL, Cahn J-Y, Schouten H, Finke J, Ball ED, Aljurf M, Cutler C, Rowe JM, Antin JH, Isola LM, DiBartolomeo P, **Camitta B**, Miller AM, Cairo MS, Stockerl-Goldstein KE, Sierra J, Savoie ML, Halter J, Stiff PJ, Nabhan C, Jakubowski AA, Bunjes D, Petersdorf EW, Devine SM, Maziarz R, Bornhauser M, Lewis VA, Marks DI, Bredeson CN, Soiffer R, Weisdorf DJ. Cytogenetics abnormalities predict the outcome of allogeneic transplantation in AML: a CIBMTR study. *Blood*. 2010;116:299a
176. Urtishak KA, Wang L-S, Harvey R, Atlas SR, Chen I-M, Robinson BW, Moukartzel L, Cao K, Devidas M, Carroll AJ, Heerema NA, Hunger S, Reaman GH, Hilden JM, **Camitta B**, Winick N, Carroll WL, Zhang AY, Cori L, McVeigh S, Barrett JS, Dreyer ZE, Willman CL, Felix CA. Infant acute lymphoblastic leukemias are pan-sensitive to Obatoclax across molecular/cytogenetic subtypes, especially MLL-ENL, and gene expression profiles determine Obatoclax IC50: a report on the Children's Oncology Group (COG) P9407 trial. *Blood*. 2010;116:1137a
177. Chen I, Harvey R, Mullighan CG, Loh ML, Devidas M, Borowitz MJ, Tasian SK, Payne-turner D, Wharton W, Pullen J, Carroll AJ, Carroll WL, **Camitta BM**, Hunger S, Winick NJ, Willman CL. Relationship of CRLF2 expression and outcome in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL): a report from the Children's Oncology Group. *J Clin Oncol*. 2011;29:586s